US20090148533A1 - Ion binding compositions - Google Patents

Ion binding compositions Download PDF

Info

Publication number
US20090148533A1
US20090148533A1 US12/238,844 US23884408A US2009148533A1 US 20090148533 A1 US20090148533 A1 US 20090148533A1 US 23884408 A US23884408 A US 23884408A US 2009148533 A1 US2009148533 A1 US 2009148533A1
Authority
US
United States
Prior art keywords
shell
core
method
binding
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/238,844
Other versions
US8445014B2 (en
Inventor
Dominique Charmot
Han-Ting Chang
Eric Connor
Mingjun Liu
Gerrit Klaerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor (international) Ltd
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/814,749 priority Critical patent/US8192758B2/en
Priority to US10/814,527 priority patent/US7854924B2/en
Priority to US10/813,872 priority patent/US8282960B2/en
Priority to US10/965,274 priority patent/US7488495B2/en
Priority to US11/095,918 priority patent/US7429394B2/en
Application filed by Relypsa Inc filed Critical Relypsa Inc
Priority to US12/238,844 priority patent/US8445014B2/en
Publication of US20090148533A1 publication Critical patent/US20090148533A1/en
Application granted granted Critical
Publication of US8445014B2 publication Critical patent/US8445014B2/en
Assigned to CANTOR FITZGERALD SECURITIES reassignment CANTOR FITZGERALD SECURITIES SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RELYPSA, INC.
Assigned to ILYPSA, INC. reassignment ILYPSA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHARMOT, DOMINIQUE, CONNOR, ERIC, LIU, MINGJUN, CHANG, HAN-TING, KLAERNER, GERRIT
Assigned to RELYPSA, INC. reassignment RELYPSA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ILYPSA, INC.
Assigned to RELYPSA, INC. reassignment RELYPSA, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CANTOR FITZGERALD SECURITIES
Assigned to VIFOR (INTERNATIONAL) LTD. reassignment VIFOR (INTERNATIONAL) LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RELYPSA, INC.
Application status is Active legal-status Critical
Adjusted expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/80Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04Acids; Metal salts or ammonium salts thereof
    • C08F120/06Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/838Cirrhosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/869Diuretic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/87Edema
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/893Liver disorder

Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Description

    CROSS-REFERENCE
  • This application is a continuation of U.S. application Ser. No. 11/095,918, filed Mar. 30, 2005, which is a continuation-in-part of U.S. application Ser. No. 10/965,274, filed Oct. 13, 2004 which is a continuation-in-part application of U.S. application Ser. No. 10/814,527, filed Mar. 30, 2004; U.S. application Ser. No. 10/814,749, filed Mar. 30, 2004; and U.S. application Ser. No. 10/813,872, filed Mar. 30, 2004 which are incorporated herein by reference in their entirety.
  • INTRODUCTION
  • Ion selective sorbents have been used in human therapy to correct disorders in electrolyte balance, in conditions such as hyperphosphatemia, hyperoxaluria, hypercalcemia, and hyperkalemia. Hyperphosphatemia occurs in patients with renal failure, whose kidneys no longer excrete enough phosphate ions to compensate exogenous phosphate uptake in the diet. This condition leads to high serum phosphate concentration and high calcium×phosphate product. Although the etiology is not fully demonstrated, high calcium×phosphate product has been held responsible for soft tissue calcification and cardiovascular disease. Cardiovascular disease is the cause of death in almost half of all dialysis patients.
  • Aluminum, calcium, and, more recently, lanthanum salts have been prescribed to control phosphate ion absorption in the gastrointestinal (GI) tract and restore systemic phosphate levels back to normal. However these salts liberate soluble aluminum and calcium cations in the GI tract, which are then partially absorbed into the blood stream. Aluminum absorption can cause serious side effects such as aluminum bone disease and dementia; high calcium uptake leads to hypercalcemia and puts patients at risk for coronary calcification.
  • Metal-free phosphate binders such as strong base ion-exchanger materials, Dowex and Cholestyramine resins, have been suggested for use as phosphate binders. However, their low capacity of binding requires high dosage that is not well tolerated by patients.
  • Amine functional polymers have been described as phosphate or oxalate binders. For example, see U.S. Pat. Nos. 5,985,938; 5,980,881; 6,180,094; 6,423,754; and PCT publication WO 95/05184. Renagel, a crosslinked polyallylamine resin, is a phosphate sequestering material introduced in the market as a metal-free phosphate binder. In vitro phosphate binding of Renagel is approximately 6 mmol/gm in water and 2.5 mmol/gm when measured in 100 mM sodium chloride solution. The recommended dosage for the targeted patient population is typically between 5 gms/day to 15 gms/day to keep the phosphate concentration below 6 mg/dL. Published phase I clinical trials on Renagel, performed on healthy volunteers, indicate that 15 gms of Renagel decrease the phosphate urinary excretion from a baseline of 25 mmole to 17 mmole, the difference being excreted in the feces as free and polymer-bound phosphate. From these data, the in vivo capacity range can be established at 0.5-1 mmol/gm, which is much less than the in vitro capacity of 2.5 mmol/gr measured in saline. Considering only the in vitro binding capacity of Renagel measured in saline, a dosage of 15 gm of the 2.5 mmol/gm phosphate binder would bind the entire phosphorous content of the average American diet, i.e. 37 mmol/day. The discrepancy between the in vitro binding capacity and the documented low in vivo binding capacity has a negative impact on the therapeutic benefit of the drug since more resin is needed to bring the serum phosphate to a safe range.
  • This loss of capacity of ion-exchange resins is not limited to Renagel when used in the complex environment of the GI tract environment. For example, cation exchange resins in the sodium or ammonium form have been administered to patients with hyperkalemia. The exchange capacity of these resins were measured from isolated feces and found to be about 20% of the in vitro capacity (Agarwal, R., Gastroenterology, 1994, 107, 548-571).
  • Although generally safe from a toxicological perspective, the large dose and inconvenience associated with taking multigram amounts of resin (e.g., up to 15 gms/day for Renagel and considerably higher in the cases of sodium-binding resins) argues for the need to improve resin capacity. As an example, even in reported safety studies of the Renagel binder, patients have noted gastrointestinal discomfort at doses as low as 1.2-2.0 gm/day for an 8 week treatment period. Patients receiving 5.4 gm of Renagel/day were discontinued from treatment due to adverse events such as GI discomfort in 8.9% of the cases (Slatapolsky, et al Kidney Int. 55:299-307, 1999; Chertow, et al Nephrol Dial Transplant 14:2907-2914, 1999). Thus, an improvement in in vivo binding capacity that translates to lower, better tolerated dosing would be a welcome improvement in resin-based therapies.
  • As a result of these considerations there is still a great need for safe, high-capacity binders that selectively remove ions from the body with a lower drug dosage and a better patient compliance profile.
  • SUMMARY OF THE INVENTION
  • In one aspect, the present invention provides core-shell compositions and pharmaceutical compositions thereof. The core-shell compositions of the present invention comprise of a core component and a shell component. In a preferred embodiment, the core of the core-shell composition is a polymer and can preferentially bind one or more target solutes, e.g., in the gastrointestinal (GI) tract of an animal. In another preferred embodiment, the permeability of the shell component is modified based on the external environment.
  • Another aspect of the invention provides methods for treatment of patients using the core-shell compositions described herein. In a preferred embodiment, the core-shell compositions are used to remove target solutes from the GI tract. Examples of target solutes that can be removed from the GI tract include, but are not limited to, phosphate, oxalate, sodium, chloride, protons, potassium, iron, calcium, ammonium, magnesium, urea, and creatinine. In another preferred embodiment, the compositions described herein are used in the treatment of hyperphosphatemia, hypocalcemia, hyperparathyroidism, depressed renal synthesis of calcitriol, tetany due to hypocalcemia, renal insufficiency, ecotopic calcification in soft tissues, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload, sodium overload, hyperkalemia, metabolic acidosis, renal insufficiency, and anabolic metabolism.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a schematic representation of one embodiment of a core-shell composition.
  • FIG. 2 depicts the solute binding profile as a function of time for some embodiments of the invention.
  • FIG. 3 depicts the membrane preparation for determination of ion permeability.
  • FIG. 4 depicts the binding data of different polyethyleneimine coated beads for different cations.
  • FIG. 5 depicts the effect of a Eudragit RL 100 shell on magnesium and potassium binding.
  • FIG. 6 depicts binding of magnesium on benzylated polyethyleneimine coated Dowex (K) beads.
  • FIG. 7 depicts the stability of Ben(84)-PEI coated Dowex (K) beads under acid conditions representative of the acidic conditions in the stomach.
  • FIG. 8 depicts potassium and magnesium binding by Dowex beads coated with benzylated polyethyleneimine.
  • FIG. 9 depicts magnesium binding by fluoroacrylic acid beads with benzylated polyethylene imine shell.
  • FIG. 10 depicts a setup for determining membrane permeability.
  • FIG. 11 depicts the permeability of benzylated polyethyleneimine membrane.
  • FIG. 12 depicts the permeability and permselectivity of membranes comprising of mixtures of Eudragit RL 100 and Eudragit RS 100.
  • FIG. 13 depicts the effects of bile acids on potassium binding by Dowex(Li) coated with polyethyleneimine.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides core-shell polymeric compositions. Also, methods and kits for using these compositions are described herein.
  • Core Shell Compositions
  • One aspect of the invention is a core-shell composition comprising a core component and a shell component. In a preferred embodiment, the core-shell composition is a polymeric composition and the core component can preferentially bind one or more target solutes, e.g., in the gastrointestinal (GI) tract of an animal. The term “animal” and “animal subject” as used herein includes humans as well as other mammals.
  • As shown in FIG. 1, in one embodiment, the core-shell composition comprises core-shell particles with a core component 2 and a shell component 4. The core component is capable of preferentially binding one or more target solutes and the shell component has a higher permeability for the target solutes compared to the permeability for one or more competing solutes. The size of the arrows in FIG. 1 corresponds to the magnitude of the permeability of the solutes. In preferred embodiments, the shell of the core-shell composition is essentially not disintegrated during the period of residence and passage through the gastro-intestinal tract.
  • The term “target solute” as used herein means a solute that is preferentially bound and/or retained by the core component of the core-shell composition. It is preferred that the target solute has a higher permeability across the shell compared to one or more competing solutes. In preferred embodiments, the shell preferentially allows contact of the target solute with the core. Target solutes include both ions and non-ionic molecules. The ions include both organic and inorganic ions. The ions also include hydrophilic ions, hydrophobic ions, hydrophilic neutral molecules, and hydrophobic neutral molecules. Examples of anionic target solutes include phosphate, chloride, bicarbonate, and oxalate ions. Examples of cationic target solutes include protons, sodium, potassium, magnesium, calcium, ammonium, and other heavy metal ions. Target solutes also include toxins such as uremic toxins. Examples of uremic toxins include urea, creatinine, and classes of compounds such as ribonucleosides, guanidines, polyols, peptides, purines, pyrimidines. See Vanholder et al., Kidney International, vol. 63, (2003), 1934-1943.
  • In one embodiment, the target solutes excludes high molecular weight molecules like proteins, polysaccharides, and cell debris whose molecular weight are greater than about 50,000 daltons, preferably greater than 5000 daltons. Target solutes also include non-ionic molecules such as organic and inorganic neutral molecules, as well as hydrophilic and hydrophobic neutral molecules. For example, the non-ionic molecules include biological toxins, enzymes, metabolites, drugs, bodily secretions, hormones, etc. Typically, the toxins bound by the compositions disclosed herein are less than about 10,000 daltons, preferably less than 5000 daltons, and even more preferably less than 2000 daltons. The compositions disclosed herein with suitable properties could be used to treat toxicities caused by uremia, drug overdoses or exposure to toxins such as biological toxins or chemical contaminants.
  • In one embodiment, the core-shell particle preferably binds target solutes, excluding bile acids. In another embodiment, the core-shell particle preferably binds a bile acid and one additional target solute which is not a bile acid.
  • The term “competing solute” as used herein means solutes that compete with the target solute for binding to a core component, but that are not desired to be contacted and/or bound to the core component. Typically, the competing solute for a core-shell composition depends on the binding characteristics of the core and/or the permeability characteristics of the shell component. A competing solute can be prevented from contacting and/or binding to a core-shell particle due to the preferential binding characteristics of the core component and/or the decreased permeability of the shell component for the competing solute from the external environment. Typically, the competing solute has a lower permeability from the external environment across the shell compared to that of the target solute. For example, for a core-shell composition with a core component that preferably binds phosphate ions, an example of a competing solute is bile acids and fatty acids. The bile acids and fatty acids can be kept away from the core and not be allowed to bind to the core due to the permeability barrier created by the shell component that is more permeable to phosphate ions than bile acids.
  • In one embodiment, the target solute is hydrophilic ions. The core-shell polymeric compositions which have hydrophilic ions as target solutes are preferably used to remove hydrophilic ions from physiological fluids. More preferably, such core-shell compositions have utility in selectively removing phosphate, oxalate and/or chloride anions. In another embodiment, the hydrophilic ions removed are sodium and/or potassium ions.
  • It is preferred that the core component of the core-shell particles preferentially binds at least one target solute. The term “preferential binding” and its grammatical equivalents are used herein to describe the favored binding of the target solute to the core component and/or core-shell particles compared to the binding of competing solutes. The preferential binding of target solute can be due to a higher binding affinity for target solutes compared to competing solutes. Preferential binding also encompasses an increased amount of binding of target solutes by the core component, compared to the binding of competing solutes. In some of the preferred embodiments, the core-shell particles bind a greater amount of target solute compared to the core by itself in the absence of the shell. The increased amount of binding can be from about 5% to 100%. It is preferred that the increase in binding of target solute in the presence of the shell compared to the amount bound in the absence of the shell is about 10% or greater, more preferred is about 25% or greater, even more preferred is about 50% or greater, and most preferred is about 95% or greater.
  • It is also preferred that the core-shell particles retain a significant amount of the bound target solute. The term “significant amount” as used herein is not intended to mean that the entire amount of the bound target solute is retained. It is preferred that at least some of the bound solute is retained, such that a therapeutic and/or prophylactic benefit is obtained. Preferred amounts of bound target solutes that are retained range from about 5% to about 100%. It is preferred that the core-shell compositions retain about 50% of the bound target solute, more preferred is about 75%, and even more preferred is greater than 95%. The period of retention of the bound sodium is preferred to be during the time that the core-shell composition is being used therapeutically and/or prophylactically. In the embodiment in which the core-shell composition is used to bind and remove target solutes from the gastro-intestinal tract, the retention period is preferred to be during the time of residence of the composition in the gastro-intestinal tract. For a topical preparation or a core-shell composition used for a local effect, the retention time is typically the period the composition is present on the topical location or the location that the local effect is desired.
  • In one embodiment, the core component is composed of polymers containing functional groups with specific binding properties for a given solute, i.e. the target solute. The functional groups with the desired binding properties can be incorporated in the polymer backbone or pendant to the backbone. The binding interactions between the target solutes and the functional groups of the binding core can be of various kinds including, but not limited to, acid-base, coulombic, dipolar, hydrogen bonding, covalent binding, Pi interaction, and combinations thereof.
  • In different embodiments of the invention, the preferential binding between the target solute and the competing solutes can be controlled by the rate of sorption of solutes within the core material or by the rate of permeation of the solutes across the shell component. That is, it is possible to modify the affinity of a target solute for the core component by modifying the overall permeation rate across the particle while keeping the binding core characteristics constant. Also, it is possible to reverse the selectivity for a set of solutes for a given binding core, by creating a permeability coefficient difference in the shell.
  • Some of the characteristics of the shell membrane and the solutes that influence the permeation of solutes across the core-shell particles are:
      • size and shape of the hydrated solute;
      • degree of association/aggregation of the solute (e.g., when micelles are formed);
      • charge of the solutes;
      • hydration ratio of the shell;
      • mesh size of the shell; and
      • interaction between shell and solutes.
  • Other parameters also influence the overall mass transfer of solutes to the interior of the core-shell particles:
      • specific surface area (i.e. particle diameter);
      • thickness of the shell; and
      • convection current at the outside of the particles.
  • When there are no chemical interactions between the polymeric composition and the solute, the diffusion can be described by Fick's first law:
  • J s = P l 8 ( C o - C i )
      • where JS is the solute flux in g/cm2/s;
      • L is the membrane thickness (cm);
      • P is the permeability coefficient in cm2/s; and
      • C0-Ci is the concentration gradient across the membrane.
        The permeability coefficient is expressed as:

  • P=KD
      • where K is a dimension-less parameter (assimilated to the solute partition coefficient between the membrane and the solution) and
      • D is the solute coefficient in the aqueous solution.
        Several models are known to express the permeability coefficient P, such as the capillary pore model (Renkin equation) and the free volume model, among others.
  • In the free volume model, the polymeric composition that makes up the core and/or shell component is considered to be a homogenously hydrated network. The diffusion transport of solutes is considered to occur through fluctuating water-filled spaces within the polymeric network. The free volume diffusion model predicts that D scales with the fraction of polymer in the membrane, φ, and the radius of the hydrated solute, rs. A refinement has been proposed (Peppas et al., J. Appl. Polym. Sci., 36,735-747, 1988) as the hydrodynamic model:
  • D D 0 = k 1 exp [ - k r s 2 ( φ 1 - φ ) ] diffusion model D D 0 = exp [ - k c r s φ 3 / 4 ] hydrodynamic model
      • where D and D0 are the diffusion coefficients in the membrane and the aqueous solution, respectively and
      • k1 is related to the sieving factor, when the geometry of the solute is the critical parameter that dictates the solute progression in the core-shell composition and k′ and kc are undefined structural factors.
  • For a target solute such as phosphate ions, a typical value of self-diffusion coefficient is 10−5 cm2/s. Based on certain diffusion models, the permeation rate across a micron thick shell membrane is estimated to be extremely fast with respect to the time of use of the resin, typically hours.
  • If bile acid or fatty acid molecules, as the competing solutes, compete for the same core binding sites as phosphate ions, their self-diffusion coefficient is inversely proportional to their size in solution, which is not so different from one of small ions. Thus, this self-diffusion coefficient may not be enough to create a permeability barrier, if the diffusion is unhindered. Accordingly, in some embodiments, several characteristics of the shell component are tuned so that a permeation difference is established. For example, when the mesh size of the shell material is in the same size range as the solute dimensions, the random walk of the bulkier solute through the shell component is significantly slowed down. For example, experimental studies (Krajewska, B., Reactive and Functional polymers 47, 2001, 37-47) report permeation coefficients in cellulose ester or crosslinked chitosan gel membranes for both ionic and non-ionic solutes shows slowing down of bulkier solutes when mesh size nears solute dimensions. Accordingly, D values can decrease several orders of magnitude depending on the molecular size of the solutes and the polymer volume fraction in the core-shell compositions, the polymer volume fraction in the swollen resin being a good indicator of the mesh size within the composition. Theoretical studies have shown, for example, that mesh size usually scales with φ−3/4, φ being the polymer volume fraction in the shell component when swollen in a solution.
  • In some embodiments, the permeability of the solute is modulated by the degree of interaction between the solute and the shell material. A strong interaction can trap the solute inside the shell component, almost shutting down the migration across the shell. Examples of types of interaction include ionic, covalent, polar, hydrogen bonding, van der Waals, and hydrophobic interactions.
  • In some embodiments, depending upon the conditions of use and the type of solutes, the ratio between the diffusion coefficient of the target solute and the competing solutes through the shell, is between about 1.1:1 to about 109:1, preferably between about 2:1 to about 106:1.
  • When the core-shell particles of the invention are used, the solute binding profile as a function of time, of some embodiments, can be schematically represented as depicted in FIG. 2. In a preferred embodiment, the target solute migrates quickly through the shell to be bound to the core material quickly attaining its binding value corresponding to a non-competing mode. In contrast, the competing solute slowly progresses through the shell as a result of its lower permeation rate; it eventually reaches its binding equilibrium value later in time and then displaces the target solute, causing a drop in the target solute binding curve. Preferably the ratio of diffusion coefficients is adjusted so that, at the end of the time of use of the binder (which may correspond to mean residence time of the resin in the GI) is less than about 10% to about 100% of the competing solutes have reached their binding equilibrium value. Preferably less than about 10%, more preferably less than about 50%, and even more preferably less than about 75% of the competing solutes have reached their binding equilibrium value. For the target solutes more than about 10% to about 100% has reached its binding equilibrium value in a non-competing mode. Preferably more than about 25%, more preferably more than about 50%, even more preferably more than about 75% of the target solute has reached its binding equilibrium.
  • Methods for determining diffusion coefficients are known. For example, see, W. Jost, Diffusion in Solids, Liquids and Gases, Acad. Press, New-York, 1960). For example, the diffusion coefficient of a shell polymer can be measured by casting it as a membrane over a solid porous material, which is then contacted with a physiological solution containing the solutes of interest, and measuring steady state permeation rates of said solutes. Membrane characteristics can then be optimized to achieve the best cooperation in terms of selectivity and permeation rate kinetics. Structural characteristics of the membrane can be varied by modifying, for example, the polymer volume fraction (in the swollen membrane), the chemical nature of the polymer(s), the polymer blend composition (if more than one polymer is used), the formulation with additives such as wetting agents, plasticizers, and the manufacturing process.
  • Alternatively, if the shell membrane is applied to the core material in a separate coating process, then the selectivity effect provided by the shell can be obtained by measuring the binding capacity for the target solute using the core particles with and without the shell. The increase in selectivity, SI, can be simply expressed as the ratio of those two values, i.e. SI=CBcore-shell/CBcore, where CB represent the capacity of binding (i.e mole of solute per unit weight of particle). Preferably, SI is between about 1.05 to about 104, even more preferably from about 1.1 to about 102.
  • In some embodiments, the shell is a film-forming polymer. In another embodiment, the shell polymer forms a crosslinked gel with a three-dimensional network structure where chains are crosslinked through covalent bonds, ionic or other bonds. In yet another embodiment, the shell material is chemically identical to the binding core material, but the crosslink density increases outward from core to shell. In another embodiment, the shell material adopts a “brush” configuration, wherein individual polymer strands are covalently attached to the core material at their termini. In this embodiment, the mesh size can be dictated by the density of chains anchored onto the surface and by the chain molecular weight. The polymer brush design variables that control the permeability of polymer brushes to solutes of various sizes and/or weights are known in the art. For example, see WO 0102452 (and references therein).
  • Permeability is also controlled by the interaction of the solute with the shell. A strong and, preferably, irreversible interaction of the shell with the competing solutes can trap the competing solutes within the encapsulating shell, slowing down their progression inward. One means of quantifying the degree of interaction between a solute and the shell is the free energy of mixing, particularly the free enthalpy of mixing, which can be predicted by solubility parameters. Solubility parameters provide a numerical method of predicting the extent of interaction between materials, particularly liquids and polymers. This model predicts that compounds with dissimilar solubility parameters will not co-dissolve and consequently can go through the membrane unhindered in the absence of size sieving effect. Conversely, compounds with similar solubility parameters may form a molecular solution and can be retained. Further, while solubility parameters poorly describe ionic interactions, charged solutes generally are retained by shell material of opposite charge. Also, the combination of hydrophobic and ionic interactions can be used to provide strong, often irreversible, interactions with competing solutes, resulting in higher sorption selectivity for the target solutes which display neither a hydrophobic or an ionic character.
  • The shell material can be chosen from natural or synthetic polymers, optionally crosslinked, alone or in combination with small molecules functional additives such as wetting agents, plasticizers, permeability enhancers, solvents, moisturizing agents, pigment, and/or dyes.
  • Naturally-occurring or semi-synthetic polymers include: cellulose ethers (ethyl cellulose, methyl cellulose and their copolymers), cellulose esters (cellulose acetate, cellulose propionate, cellulose phthalate, and their copolymers), hydroxypropyl cellulose, hydroxyl ethyl cellulose, chitosan, deacetylated chitosan, and the like. Other examples of possible shell materials are listed in the table below:
  • TABLE 1
    Acrylics
    Aquacoat ® aqueous dispersions
    Aquateric ® enteric coatings
    Cellulose Acetate
    Cellulose Acetate Butyrate
    Cellullose Acetate Phthalate
    Caseinates
    Chlorinated rubber
    Coateric ® coatings
    Coating butters
    Daran ® latex
    Dextrins
    Ethyl Cellulose
    Enterics
    Eudragits ® polymethacrylates
    Ethylene Vinyl Acetate
    Fats
    Fatty Acids
    Gelatin
    Glycerides
    Gums, vegetable
    Gums, vegetable
    Halocarbon
    Hydrocarbon resins
    Hydroxy Propyl Cellulose
    Hydroxy Propyl Methyl
    Cellulose
    Hydroxy Propyl Methyl
    Cellulose Phthalate
    Kynar ® fluoroplastics
    Maltodextrins
    Methyl Cellulose
    Microcrystalline wax
    Milk solids
    Molasses
    Nylon
    Opadry ® coating systems
    Paraffin wax
    Phenolics
    Polylactides
    Polyamino acids
    Polyethylene
    Polyethylene glycol
    Polyvinyl acetate
    Polyvinyl pyrrolidone
    Polyvinyl alcohol
    Polyvinyl chloride
    Polyvinylacetate phthalate
    Polyvinylidene chloride
    Proteins
    Rubber, synthetic
    Shellac
    Silicone
    Starches
    Stearines
    Sucrose
    Surfactants
    Surelease ® coating systems
    Teflon ® fluorocarbons
    Waxes
    Zein
  • Examples of suitable synthetic polymers that can be used in the shell component include polymers produced by free radical polymerization of ethylenic monomers (acrylic and methacrylic, styrenic, dienic, vinylic), polycondensates (polyester, polyamides, polycarbonate, polysulfone), polyisocyanate, polyurea, epoxy resins, and the like.
  • Shell deposition over the core material can be carried out using coating techniques such as spraying, pan coating, fluidized bed (Wurster coating units), dipping, solvent coacervation, polyelectrolyte inter-complex layers, and the “layer by layer” encapsulation process. Other encapsulation processes are also applicable. For example, see Encapsulation and Controlled Release by R. A. Stephenson (Editor), David R. Karsa (Editor), 1993.
  • The shell can comprise several layers of distinct composition, of which one can be an enteric coating (e.g. Eudragit acrylic polymers) that disintegrates and/or solubilizes at a specific location of the GI tract. Examples of suitable enteric coatings are known in the art, for example see Remington: The Science and Practice of Pharmacy by A. R. Gennaro (Editor), 20th Edition, 2000.
  • The shell can also be grown on the core component through chemical means, for example by:
      • chemical grafting of shell polymer to the core using living polymerization from active sites anchored onto the core polymer;
      • interfacial reaction, i.e., a chemical reaction located at the core particle surface, such as interfacial polycondensation; and
      • using block copolymers as suspending agents during the core particle synthesis.
  • The interfacial reaction and use of block polymers are preferred techniques when chemical methods are used. In the interfacial reaction pathway, typically, the periphery of the core particle is chemically modified by reacting small molecules or macromolecules on the core interface. For example, an amine containing ion-binding core particle is reacted with a polymer containing amine reactive groups such as epoxy, isocyanate, activated esters, halide groups to form a crosslinked shell around the core.
  • In another embodiment, the shell is first prepared using interfacial polycondensation or solvent coacervation to produce capsules. The interior of the capsule is then filled up with core-forming precursors to build the core within the shell capsule.
  • Solvent coacervation is described in the art. For example, see Leach, K. et al., J. Microencapsulation, 1999, 16(2), 153-167. In this process, typically two polymers, core polymer and shell polymer are dissolved in a solvent which is further emulsified as droplets in an aqueous phase. The droplet interior is typically a homogeneous binary polymer solution. The solvent is then slowly driven off by careful distillation. The polymer solution in each droplet undergoes a phase separation as the volume fraction of polymer increases. One of the polymer migrates to the water/droplet interface and forms a more-or less perfect core-shell particle (or double-walled microsphere).
  • Solvent coacervation is one of the preferred methods to deposit a controlled film of shell polymer onto the core. In one embodiment, the coacervation technique consists in dispersing the core beads in a continuous liquid phase containing the shell material in a soluble form. The coacervation process then consists of gradually changing the solvency of the continuous phase so that the shell material becomes increasingly insoluble. At the onset of precipitation some of the shell material ends up as a fine precipitate or film at the bead surface. The change in solvency can be triggered by a variety of physical chemistry means such as, but not limited to, changes in pH, ionic strength (i.e. osmolality), solvent composition (through addition of solvent or distillation), temperature (e.g when a shell polymer with a LCST (lower critical solution temperature) is used), pressure (particularly when supercritical fluids are used). More preferred are solvent coacervation processes when the trigger is either pH or solvent composition. Typically when a pH trigger event is used and when the polymer is selected from an amine type material, the shell polymer is first solubilized at low pH. In a second step the pH is gradually increased to reach the insolubility limit and induce shell deposition; the pH change is often produced by adding a base under strong agitation. Another alternative is to generate a base by thermal hydrolysis of a precursor (e.g. thermal treatment of urea to generate ammonia). The most preferred coacervation process is when a ternary system is used comprising the shell material and a solvent/non-solvent mixture of the shell material. The core beads are dispersed in that homogeneous solution and the solvent is gradually driven off by distillation. The extent of shell coating can be controlled by on-line or off-line monitoring of the shell polymer concentration in the continuous phase. In the most common case where some shell material precipitates out of the core surface either in a colloidal form or as discrete particle, the core-shell particles are conveniently isolated by simple filtration and sieving. The shell thickness is typically controlled by the initial core to shell weight ratio as well as the extent of shell polymer coacervation described earlier. The core-shell beads can then be annealed to improve the integrity of the outer membrane as measured by competitive binding.
  • In some embodiments, using the block copolymer approach, an amphiphilic block copolymer can be used as a suspending agent to form the core particle in an inverse or direct suspension particle forming process. When an inverse water-in-oil suspension process is used, then the block copolymer comprises a first block soluble in the continuous oil phase and another hydrophilic block contains functional groups that can react with the core polymer. When added to the aqueous phase, along with core-forming precursor, and the oil phase, the block copolymer locates to the water-in-oil interface and acts as a suspending agent. The hydrophilic block reacts with the core material, or co-reacts with the core-forming precursors. After the particles are isolated from the oil phase, the block copolymers form a thin shell covalently attached to the core surface. The chemical nature and length of the blocks can be varied to vary the permeation characteristics of the shell towards solutes of interest.
  • In systems which combine positive charges and hydrophobicity, preferred shell polymers include amine functional polymers, such as those disclosed above, which are optionally alkylated with hydrophobic agents.
  • Alkylation involves reaction between the nitrogen atoms of the polymer and the alkylating agent (usually an alkyl, alkylaryl group carrying an amine-reactive electrophile). In addition, the nitrogen atoms which do react with the alkylating agent(s) resist multiple alkylation to form quaternary ammonium ions such that less than 10 mol % of the nitrogen atoms form quaternary ammonium ions at the conclusion of alkylation.
  • Preferred alkylating agents are electrophiles such as compounds bearing functional groups such as halides, epoxides, esters, anhydrides, isocyanate, or αβ-unsaturated carbonyls. They have the formula Rx where R is a C1-C20 alkyl (preferably C4-C20), C1-C20 hydroxy-alkyl (preferably C4-C20 hydroxyalkyl), C6-C20 aralkyl, C1-C20 alkylammonium (preferably C4-C20 alkyl ammonium), or C1-C20 alkylamido (preferably C4-C20 alkyl amido) group and X includes one or more electrophilic groups. By “electrophilic group” it is meant a group which is displaced or reacted by a nitrogen atom in the polymer during the alkylation reaction. Examples of preferred electrophilic groups, X, include halide, epoxy, tosylate, and mesylate group. In the case of, e.g., epoxy groups, the alkylation reaction causes opening of the three-membered epoxy ring.
  • Examples of preferred alkylating agents include a C3-C20 alkyl halide (e.g., an n-butyl halide, n-hexyl halide, n-octyl halide, n-decyl halide, n-dodecyl halide, n-tetradecyl halide, n-octadecyl halide, and combinations thereof); a C1-C20 hydroxyalkyl halide (e.g., an 11-halo-1-undecanol); a C1-C20 aralkyl halide (e.g., a benzyl halide); a C1-C20 alkyl halide ammonium salt (e.g., a (4-halobutyl) trimethylammonium salt, (6-halohexyl)trimethyl-ammonium salt, (8-halooctyl)trimethylammonium salt, (10-halodecyl)trimethylammonium salt, (12-halododecyl)-trimethylammonium salts and combinations thereof); a C1-C20 alkyl epoxy ammonium salt (e.g., a (glycidylpropyl)-trimethylammonium salt); and a C1-C20 epoxy alkylamide (e.g., an N-(2,3-epoxypropane)butyramide, N-(2,3-epoxypropane) hexanamide, and combinations thereof). Benzyl halide and dodecyl halide are more preferred.
  • The alkylation step on the polyamine shell precursor can be carried out in a separate reaction, prior to the application of the shell onto the core beads. Alternatively the alkylation can be done once the polyamine shell precursor is deposited onto the core beads. In the latter case, the alkylation is preferably performed with an alkylating agent that includes at least two electrophilic groups X so that the alkylation also induces crosslinking within the shell layer. Preferred polyfunctional alkylation agents include di-halo alkane, dihalo polyethylene glycol, and epichlorohydrine. Other crosslinkers containing acyl chlorides, isocyanate, thiocyanate, chlorosulfonyl, activated esters (N-hydroxysuccinimide), carbodiimide intermediates, are also suitable.
  • Typically, the level of alkylation is adjusted depending upon the nature of the polyamine precursor and the size of the alkyl groups used on alkylation. Some factors that play a role in the level of alkylation include:
      • (a) Insolubility of the shell polymer under conditions of the GI tract. In particular, the low pH's prevailing in the stomach tend to solubilize alkylated polyamine polymers whose pH of ionization is 5 and above. For that purpose higher rate of alkylation and higher chain length alkyl are preferred. As an alternative, one may use an enteric coating to protect the shell material against acidic pH's, said enteric coating is released when the core-shell beads are progressing in the lower intestine.
      • (b) The permselectivity profile: When the alkylation ratio is low the persistence of the permselectivity for competing ions (e.g. Mg2+, Ca2+) can be shorter than the typical residence time in the colon. Conversely when the alkylation ratio (or the weight fraction of hydrophobes) is high then the material becomes almost impermeable to most inorganic cations, and thus, the rate of equilibration for K+ becomes long.
        Preferably, the degree of alkylation is selected by an iterative approach monitoring the two variables mentioned above.
  • In a preferred embodiment, the shell is formed with Eudragit, for example Eudragit RL 100 or RS 100 or a combination thereof, or with polyethyleneimine (PEI). These shells maybe applied by solvent coacervation technique. The PEI may be optionally benzylated and also optionally cross-linked. Examples of suitable cross-linkers include but are not limited to
  • Figure US20090148533A1-20090611-C00001
  • In some embodiments, the shell thickness can be between about 0.002 micron to about 50 micron, preferably about 0.005 micron to about 20 microns. Preferably the shell thickness is more than about 1 micron, more preferred is more than about 10 micron, even more preferred is more than about 20 micron, and most preferred is more than about 40 micron. Preferably the shell thickness is less than about 50 micron, more preferred is less than about 40 micron, even more preferred is less than about 20 micron, and most preferred is less than about 10 micron.
  • In another embodiment, the shell to core weight ratio comprises between about 0.01% to about 50%, preferably between about 0.2% to about 10%. The size of the core-shell particles typically range from about 200 nm to about 2 mm, preferably being about 500 μm. Preferably the size of the core-shell particles are more than about 1 μm, more preferred is more than about 100 μm, even more preferred is more than about 200 μm, and most preferred is more than about 400 μm. Preferably the size of the core-shell particles are less than about 500 μm, more preferred is less than about 400 μm, even more preferred is less than about 200 μm, and most preferred is less than about 100 μm. The binding selectivity of the core can be assessed by standard methods. One method consists of measuring the binding capacity of the target solute in a simple model solution with non interfering species, Cm, and in a simulant medium (Cs), and calculating a selectivity index as SI=Cs/Cm. The core-shell particles of the invention are expected to have selectivity indexes SI significantly higher than those reported for known prior-art sorbent resins.
  • In one embodiment, the permeability of the shell changes as a function of time. In particular, the permeability of the shell may change over time when used in vivo. For example, in certain applications it is preferable to either diminish or conversely increase the permeability to target solutes over time during residence in a GI tract. For example, the resin could bind a hydrophilic ionic solute at a certain location of the GI tract at a rate controlled by the solute concentration in equilibrium with the resin at that location. As the resin travels down the GI tract, the local target solute concentration may vary as a result of dilution or solute transport across the gut membrane. In this embodiment, the shell material is engineered to respond to such concentration or other physiological changes in the GI, so that its permeability is altered; more specifically, the permeability of the shell maybe decreased during its journey through the GI so that hydrophilic ions are no longer able to cross the shell membrane, during the later period of the core-shell composition's residence in the GI tract. This embodiment also applies to more hydrophobic solutes such as bile acids. In the case of bile acid sequesterants, studies have shown that the poor binding rate in vivo is caused by the release of bile acids past the ileum segment of the gut. At that point, bile acids are almost quantitatively reabsorbed by the mucosa, so that the binding equilibrium is shifted and the sequestering capacity is lowered. In this embodiment, the shell component has a permeability trigger that decreases the permeability of the shell to bile acids, when the core-shell resin passes the ileum so that the overall capacity is conserved.
  • One manner of achieving this loss of permeability to hydrophilic ions involves decreasing or even eliminating the free volume of permeation of the shell membrane. The free volume of permeation of the membrane can be modified by controlling the hydration rate of the shell. In this manner, it is possible to almost shut down the rate of permeation by inducing a shell collapse. While there are many ways to induce such a phase change, the preferred approach consists of rendering the membrane material increasingly hydrophobic so that the hydration rate decreases almost to zero. This can be accomplished through several ways depending upon the type of triggering mechanism. For example the triggering mechanism can be by pH change. The pH profile of the gastrointestinal tract presents several domains which may change as a function of time, but show some invariants indicated below (Fallinborg et al. Aliment. Pharm. Therap. (1989), 3,605-613):
  • TABLE 2
    GI tract segment Ph range
    Stomach 1-2
    Duodenum-distal small intestine 6-7
    Ceacum-ascending colon   7-5.5
    Transverse-descending colon 5.5-6  
    Feces 6.5
  • Shell polymers exhibiting a chain collapse in any of these pH regions would be prone to permeability changes. For instance, core-shell particles suitable for binding a solute selectively in the stomach and keeping it in the particle core while the particles are moving down the small and large intestine, would display high permeability to solutes at low pH and very low permeability at neutral pH. This can be done by having a shell polymer with hydrophobic groups and groups that ionize subject to pH change. For example, polymers built from hydrophobic monomers (e.g. long chain alcohol (meth)arylates, Nalkyl(meth)acrylamide), and basic monomers that ionize at low pH and remain neutral beyond their pKa (e.g. vinyl-pyridine, dialkylaminoethyl (meth)acrylamide) can be used. The relationship between pH and shell swelling ratio, and hence permeability, can be controlled by the balance of hydrophobic monomers and ionizable monomers. Examples of such systems are reported in the literature. For example, see Batich et al, Macromolecules, 26, 4675-4680. A further drop in permeability may be desirable when pH increases (e.g. from ileum to colon) to prevent bound electrolytes being released as the resin environment changes. This can be achieved where the shell material switches from a hydrated state to a collapsed, impermeable state as the pH gets slightly basic. In such embodiments, shell polymers typically contain a balanced amount of hydrophobic and acidic monomers. Such systems are extensively described in the literature. For example, see Kraft et al. Langmuir, 2003, 19, 910-915; Ito et al, Macromolecule, (1992), 25, 7313-7316.
  • Another means of changing shell permeability is by passive absorption. As described above, components present in the GI tract, whether coming from the diet, produced as diet digest metabolites, from secretion, etc. are susceptible to adsorption on and within the shell in a quasi-irreversible manner and this adsorption may modify the permeability pattern by inducing membrane collapse. The vast majority of these GI tract components is negatively charged and shows various levels of hydrophobicity. Some of these species have an amphiphilic character, such as fatty acids, bile acids, phospholipids, and biliary salts and behave as surfactants. Surfactants can adsorb non-specifically to surfaces through hydrophobic interactions, ionic interaction and combinations thereof. In the context of the present invention, this phenomenon can be used to change the permeability of the resin upon the course of binding to these surfactants during the resin's residence in the GI tract.
  • For example, fatty acids and bile acids both form insoluble complexes when mixed with positively charged polymers. For example, see Kaneko et al, Macromolecular Rapid Communications, 2003, 24(13), 789-792). Both types of molecules present similarities with synthetic anionic surfactants, and numerous studies report the formation of insoluble complexes between anionic surfactants and cationically charged polymers. For example, see Chen, L. et al, Macromolecules (1998), 31(3), 787-794. In this embodiment, the shell material is selected from copolymers containing both hydrophobic and cationic groups, so that the shell forms a complex, preferably a tight complex, with anionically charged hydrophobes typically found in the GI tract, such as bile acids, fatty acids, bilirubin and related compounds. Suitable compositions also include polymeric materials described as bile acids sequestering agents, such as those reported in U.S. Pat. No. 5,607,669, U.S. Pat. No. 6,294,163, U.S. Pat. No. 5,374,422, Figuly et al, Macromolecules, 1997, 30, 6174-6184. The formation of this complex induces a shell membrane collapse which in turn lowers or shuts down the permeation rate across the said membrane.
  • The shell permeability may also be modulated by enzymatic transformation. In one embodiment the shell comprises a hydrophobic backbone with pendant hydrophilic entities that are cleaved off via an enzymatic reaction in the gut. As the enzymatic reaction proceeds, the polymer membrane becomes more and more hydrophobic, and turns from a high swollen, high permeability material to a fully collapsed low hydration membrane with minimal permeability. Hydrophilic entities can be chosen amongst natural substrates of enzymes commonly secreted in the GI tract. Such entities include amino acids, peptides, carbohydrates, esters, phosphate esters, oxyphosphate monoesters, O- and S-phosphorothioates, phosphoramidates, thiophosphate, azo groups and other similar entities. Examples of enteric enzymes which can be used to chemically alter the shell polymer include, but are not limited to, lipases, phospholipases, carboxylesterase, glycosidases, azoreductases, phosphatases, amidases and proteases.
  • In some embodiments, the core material is chosen from polymer compositions with the desired ion binding properties. Examples of suitable polymers material include, but are not limited to:
      • 1) anion binding materials such as amine functional polymers such as those described in U.S. Pat. Nos. 5,985,938; 5,980,881; 6,180,094; 6,423,754; and PCT publication WO 95/05184 and
      • 2) cation exchange polymers, such as those with acid functional groups such as carboxylate, phosphonate, sulfate, sulfonate, sulfamate functional polymers and combinations thereof.
  • Core-shell compositions that include anion binding materials are useful for the binding and removal from GI tract of phosphate, chloride, bicarbonate, and oxalate ions. The cation exchange polymers have utility in binding and removal of physiologically important cations such as protons, sodium, potassium, magnesium, calcium, ammonium, and the like or heavy metals which cause poisoning.
  • Examples of other suitable polymers for the core component are described in the following co-pending patent applications: 1) Polyamine Polymers, Attorney Docket Number: 29329-703, filed on Nov. 3, 2003, application Ser. No. 10/701,385 and 2) Crosslinked Amine Polymers, Attorney Docket Number: 29329-749.201, filed on Mar. 22, 2004, application Ser. No. 10/806,495.
  • Further examples of compositions that can be used in the core component include the phosphate binders in PCT publications WO 94/19379, WO 96/25440, WO 01/28527, WO 02/85378, WO 96/39156, WO 98/42355, WO 99/22743, WO 95/05184, WO 96/21454, and WO 98/17707; U.S. Pat. Nos. 5,698,190; 5,851,518; 5,496,545; 5,667,775; 6,083,495; and 6,509,013; and European Patent Application 01200604.5.
  • Aluminum, calcium, and lanthanum salts are used as phosphate binders. Examples of inorganic metal salts used as phosphate binders include aluminum carbonate, aluminum hydroxide gel (Amphojel®), calcium carbonate, calcium acetate (PhosLo), and lanthanum carbonate (Fosrenol). In one embodiment, the core-shell particle comprises of a core component comprising of a metal phosphate binder, such as aluminum carbonate, aluminum hydroxide gel, calcium carbonate, calcium acetate, and lanthanum carbonate.
  • In one embodiment, the core component has sodium ion binding properties. Suitable polymers that can be used in the core so as to impart the core sodium-binding properties include crown ethers. Crown ethers exhibit selectivity for certain alkali metals over others, based mainly on the hole-size of the crown ether size and the size of the metal. Crown ethers of the type 15-18 are preferred for use in sodium ion binding core components. Also, other suitable compositions for sodium binding properties are described in co-pending patent application entitled “Methods and Compositions for Treatment of Ion Imbalances,” Attorney Docket Number 29329-714.201, filed on Mar. 30, 2004, application Ser. No. 10/814,527.
  • Uses of the Core-Shell Compositions
  • In one aspect, the invention provides methods of preferentially binding solutes in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of core-shell compositions. Core shell compositions that bind hydrophillic cations and/or anions can be used to control ion homeostasis and treat electrolyte balance disorders in phosphate (hyperphosphatemia), oxalate (calcium oxalate kidney stones, oxaluria), sodium (hypertension), potassium (hyperkalemia), chloride (acidosis), or to remove toxic metals or oxidative anions in cases of poisoning.
  • The core-shell compositions with anion exchange resins are particularly useful in the binding and excretion of negatively charged ions from the body. Core-shell compositions can also be used to bind metallic ions. These compositions can be administered orally to bind and remove from an animal various negatively charged entities and metallic species from the gastro-intestinal tract. In one embodiment, the core-shell compositions of the present invention are used to remove phosphate, oxalate, bile acids, small molecules, proteins, metallic ions such as those comprised within the 6th and the 11th groups and 4th and 6th periods of the Periodic Table, also including the Lanthanoids and the Actanoids.
  • In some embodiments, the core-shell compositions with polyvicinalamines, such as those described in co-pending U.S. patent application Ser. No. 10/701,385; entitled Polyamine Polymers, Attorney Docket Number: 29329-703, filed on Nov. 3, 2003 are useful in the treatment of renal diseases, hyperphosphatemia, and the removal of bile acids, oxalates and iron from the gastrointestinal tract.
  • In some embodiments, the core-shell compositions are used in the treatment of phosphate imbalance disorders. The term “phosphate imbalance disorder” as used herein refers to conditions in which the level of phosphorus present in the body is abnormal. One example of a phosphate imbalance disorder includes hyperphosphatemia. The term “hyperphosphatemia” as used herein refers to a condition in which the element phosphorus is present in the body at an elevated level. Typically, a patient is often diagnosed with hyperphosphatemia if the blood phosphate level is, for example, above 4.5 milligrams per deciliter of blood and/or glomerular filtration rate is reduced to, for example, more than about 20%
  • Other diseases that can be treated with the methods and compositions of the present invention include hypocalcemia, hyperparathyroidism, depressed renal synthesis of calcitriol, tetany due to hypocalcemia, renal insufficiency, and ecotopic calcification in soft tissues including calcifications in joints, lungs, kidney, conjuctiva, and myocardial tissues. Also, the present invention can be used to treat ESRD and dialysis patients. In one embodiment, the core-shell compositions are used for prophylactic treatment of diseases.
  • The core-shell compositions described herein can also be used to treat diseases wherein a reduction in physiological levels of salt is desired. The core-shell compositions, depending on the ion binding properties of the core component, can be used to remove cations such as sodium and/or anions such as chloride.
  • In one embodiment, the core-shell compositions of the present invention are used to treat metallic poisoning, like iron poisoning. Iron poisoning typically is a result of children inadvertently taking iron supplement tablets. In iron overdose, binding of iron to oral charcoal, bicarbonate, deferoxamine, or magnesium hydroxide are typical treatments. Gastric lavage and profuse oral fluids are used to try to flush out the iron tablets. Non-absorbable core-shell compositions with iron chelating properties can be used for removal of metallic iron.
  • Depending on the properties of the core and/or shell components, the core-shell compositions of the present invention also show utility in binding dietary oxalate in patients who suffer from hyperoxaluria, i.e. abnormally high levels of oxalate in the urine. Elevated urine oxalate levels are one of the causes of calcium-stone formation (i.e., kidney stones). Most calcium stones are composed of calcium oxalate, either alone or in combination with calcium phosphate or calcium urate. Elevated urinary oxalate levels can result from excessive dietary intake of oxalate (dietary oxaluria), gastrointestinal disorders that lead to malabsorption of oxalate (enteric oxaluria), or an inherited enzyme deficiency that results in excessive metabolism of oxalate (primary hyperoxaluria or PH). Dietary and enteric oxaluria can be treated with diet restriction or modifications to restrict intake of foods with high oxalate content. However patient compliance is often difficult owing to the wide distribution of oxalate and purine derivatives in many foods. Calcium carbonate tablets (500-650 mg/tablet; 3 tablets per meal) can also be taken to bind and remove intestinal oxalate, but again patient compliance is difficult owing to the amount of calcium carbonate needed. Core components made of polyvicinalamines, such as those described co-pending U.S. patent application Ser. No. 10/701,385; entitled Polyamine Polymers, Attorney Docket Number: 29329-703, filed on Nov. 3, 2003, have high binding constants for oxalate and can be used to remove oxalate from the gastro-intestinal tract and subsequently lower the risk of kidney stone formation.
  • In the present invention, the core-shell compositions can be co-administered with other active pharmaceutical agents depending on the condition being treated. This co-administration can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. For example, for the treatment of hyperphosphatemia, the core-shell compositions can be co-administered with calcium salts which are used to treat hypocalcemia resulting from hyperphosphatemia. The calcium salt and core-shell composition can be formulated together in the same dosage form and administered simultaneously. Alternatively, the calcium salt and core-shell composition can be simultaneously administered, wherein both the agents are present in separate formulations. In another alternative, the calcium salt can be administered just followed by the core-shell composition, or vice versa. In the separate administration protocol, the core-shell composition and calcium salt may be administered a few minutes apart, or a few hours apart, or a few days apart.
  • The term “treating” as used herein includes achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication, amelioration, or prevention of the underlying disorder being treated. For example, in a hyperphosphatemia patient, therapeutic benefit includes eradication or amelioration of the underlying hyperphosphatemia. Also, a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For example, administration of core-shell compositions to a patient suffering from renal insufficiency and/or hyperphosphatemia provides therapeutic benefit not only when the patient's serum phosphate level is decreased, but also when an improvement is observed in the patient with respect to other disorders that accompany renal failure and/or hyperphosphatemia like ectopic calcification and renal osteodistrophy. For prophylactic benefit, the core-shell compositions may be administered to a patient at risk of developing hyperphosphatemia or to a patient reporting one or more of the physiological symptoms of hyperphosphatemia, even though a diagnosis of hyperphosphatemia may not have been made.
  • The pharmaceutical compositions of the present invention include compositions wherein the core-shell compositions are present in an effective amount, i.e., in an amount effective to achieve therapeutic or prophylactic benefit. The actual amount effective for a particular application will depend on the patient (e.g., age, weight, etc.), the condition being treated, and the route of administration. Determination of an effective amount is well within the capabilities of those skilled in the art, especially in light of the disclosure herein.
  • The effective amount for use in humans can be determined from animal models. For example, a dose for humans can be formulated to achieve circulating and/or gastrointestinal concentrations that have been found to be effective in animals.
  • The dosages of the core-shell compositions in animals will depend on the disease being, treated, the route of administration, the physical characteristics of the patient being treated, and the composition of the core and shell components. Dosage levels of the core-shell compositions for therapeutic and/or prophylactic uses can be from about 0.5 gm/day to about 30 gm/day. It is preferred that these polymers are administered along with meals. The compositions may be administered one time a day, two times a day, or three times a day. Most preferred dose is about 15 gm/day or less. A preferred dose range is about 5 gm/day to about 20 gm/day, more preferred is about 5 gm/day to about 15 gm/day, even more preferred is about 10 gm/day to about 20 gm/day, and most preferred is about 10 gm/day to about 15 gm/day.
  • In some embodiments, the amount of target solute bound and/or retained by the core-shell particles is greater than the amount if the core component is used in the absence of the shell. Hence, the dosage of the core component in some embodiments is lower when used in combination with a shell compared to when the core is used without the shell. Hence, in some embodiments of the core-shell pharmaceutical compositions, the amount of core component present in the core-shell pharmaceutical composition is less than the amount that is administered to an animal in the absence of the shell component.
  • Preferably, the core-shell compositions used for therapeutic and/or prophylactic benefits can be administered alone or in the form of a pharmaceutical composition. The pharmaceutical compositions comprise of the core-shell compositions, one or more pharmaceutically acceptable carriers, diluents or excipients, and optionally additional therapeutic agents. The compositions can be administered by injection, topically, orally, transdermally, or rectally. Preferably, the core-shell composition or the pharmaceutical composition comprising the core-shell composition is administered orally. The oral form in which the core-shell composition is administered can include powder, tablet, capsule, solution, or emulsion. The therapeutically effective amount can be administered in a single dose or in a series of doses separated by appropriate time intervals, such as hours.
  • Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Suitable techniques for preparing pharmaceutical compositions of the core-shell compositions are well known in the art.
  • In addition to the uses of the core-shell compositions described herein in the gastro-intestinal tract, these compositions can also be used for producing local effects in other parts of the body, for example in topical formulations for local effects on the skin or in systemic formulations for producing local effects in particular organs, like the liver or the heart.
  • In some embodiments the polymers of the invention are provided as pharmaceutical compositions in the form of chewable tablets. In addition to the active ingredient, the following types of excipients are commonly used: a sweetening agent to provide the necessary palatability, plus a binder where the former is inadequate in providing sufficient tablet hardness; a lubricant to minimize frictional effects at the die wall and facilitate tablet ejection; and, in some formulations a small amount of a disintegrant is added to facilitate mastication. In general excipient levels in currently-available chewable tablets are on the order of 3-5 fold of active ingredient(s) whereas sweetening agents make up the bulk of the inactive ingredients.
  • The present invention provides chewable tablets that contain a polymer or polymers of the invention and one or more pharmaceutical excipients suitable for formulation of a chewable tablet. The polymer used in chewable tablets of the invention preferably has a swelling ratio while transiting the oral cavity and in the esophagus of less than about 5, preferably less than about 4, more preferably less than about 3, more preferably less than 2.5, and most preferably less than about 2. The tablet comprising the polymer, combined with suitable excipients, provides acceptable organoleptic properties such as mouthfeel, taste, and tooth packing, and at the same time does not pose a risk to obstruct the esophagus after chewing and contact with saliva.
  • In some aspects of the invention, the polymer(s) provide mechanical and thermal properties that are usually performed by excipients, thus decreasing the amount of such excipients required for the formulation. In some embodiments the active ingredient (e.g., polymer) constitutes over about 30%, more preferably over about 40%, even more preferably over about 50%, and most preferably more than about 60% by weight of the chewable tablet, the remainder comprising suitable excipient(s). In some embodiments the polymer comprises about 0.6 gm to about 2.0 gm of the total weight of the tablet, preferably about 0.8 gm to about 1.6 gm. In some embodiments the polymer comprises more than about 0.8 gm of the tablet, preferably more than about 1.2 gm of the tablet, and most preferably more than about 1.6 gm of the tablet. The polymer is produced to have appropriate strength/friability and particle size to provide the same qualities for which excipients are often used, e.g., proper hardness, good mouth feel, compressibility, and the like. Unswelled particle size for polymers used in chewable tablets of the invention is less than about 80, 70, 60, 50, 40, 30, or 20 microns mean diameter. In preferred embodiments, the unswelled particle size is less than about 80, more preferably less than about 60, and most preferably less than about 40 microns.
  • Pharmaceutical excipients useful in the chewable tablets of the invention include a binder, such as microcrystalline cellulose, colloidal silica and combinations thereof (Prosolv 90), carbopol, providone and xanthan gum; a flavoring agent, such as sucrose, mannitol, xylitol, maltodextrin, fructose, or sorbitol; a lubricant, such as magnesium stearate, stearic acid, sodium stearyl fumurate and vegetable based fatty acids; and, optionally, a disintegrant, such as croscarmellose sodium, gellan gum, low-substituted hydroxypropyl ether of cellulose, sodium starch glycolate. Other additives may include plasticizers, pigments, talc, and the like. Such additives and other suitable ingredients are well-known in the art; see, e.g., Gennaro A R (ed), Remington's Pharmaceutical Sciences, 20th Edition.
  • In some embodiments the invention provides a pharmaceutical composition formulated as a chewable tablet, comprising a polymer described herein and a suitable excipient. In some embodiments the invention provides a pharmaceutical composition formulated as a chewable tablet, comprising a polymer described herein, a filler, and a lubricant. In some embodiments the invention provides a pharmaceutical composition formulated as a chewable tablet, comprising a polymer described herein, a filler, and a lubricant, wherein the filler is chosen from the group consisting of sucrose, mannitol, xylitol, maltodextrin, fructose, and sorbitol, and wherein the lubricant is a magnesium fatty acid salt, such as magnesium stearate.
  • The tablet may be of any size and shape compatible with chewability and mouth disintegration, preferably of a cylindrical shape, with a diameter of about 10 mm to about 40 mm and a height of about 2 mm to about 10 mm, most preferably a diameter of about 22 mm and a height of about 6 mm.
  • In one embodiment, the polymer is pre-formulated with a high Tg/high melting point low molecular weight excipient such as mannitol, sorbose, sucrose in order to form a solid solution wherein the polymer and the excipient are intimately mixed. Method of mixing such as extrusion, spray-drying, chill drying, lyophilization, or wet granulation are useful. Indication of the level of mixing is given by known physical methods such as differential scanning calorimetry or dynamic mechanical analysis.
  • Methods of making chewable tablets containing pharmaceutical ingredients, including polymers, are known in the art. See, e.g., European Patent Application No. EP373852A2 and U.S. Pat. No. 6,475,510, and Remington's Pharmaceutical Sciences, which are hereby incorporated by reference in their entirety.
  • In some embodiments the polymers of the invention are provided as pharmaceutical compositions in the form of liquid formulations. In some embodiments the pharmaceutical composition contains an ion-binding polymer dispersed in a suitable liquid excipient. Suitable liquid excipients are known in the art; see, e.g., Remington's Pharmaceutical Sciences.
  • EXAMPLES Example 1 Synthesis of Core-Shell Crosslinked Polyallylamine Particles
  • In this process, spherical particles were formed by an inverse suspension procedure wherein a prepolymer (polyallylamine) is crosslinked with epichlorohydrine. A block copolymer was used to impart mechanical stability to the droplets during the crosslinking reaction and provide a shell membrane chemically anchored to the core particle.
  • General Procedure for Block Copolymers Synthesis
  • The block copolymers were prepared by RAFT living free radical polymerization method, using a dithiocarbazide compound as a reversible chain transfer agent (CTA) and a diazonitrile free radical initiator (AMVN) indicated below:
  • Figure US20090148533A1-20090611-C00002
  • Synthesis of Poly(n-butyl acrylate-co-t-butyl acrylate) First Block
  • n-Butyl acrylate (25 g, 195 mmol) and t-butyl acrylate (25 g, 195 mmol) were combined with the CTA (173:1 Monomer:CTA, 616 mg, 2.26 mmol)) and AIBN (18.6 mg, 0.113 mmol). The monomer to CTA ratio is fixed so that the theoretical number average molecular weight (Mn) is 20,000 g.mol at 90% conversion. The solution was stirred while purging with Ar for 20 minutes at room temperature. After this time, it was heated to 65° C. under Ar while stirring for 3 hours and then cooled to room temperature. 1H NMR in CDCl3 showed 87% conversion based on disappearance of monomer. The crude polymer was dissolved in 50 ml of acetone and precipitated into 900 ml of a 9:1 (v/v) methanol: water solution. After several hours, the polymeric oil had separated to the bottom and the top layer was discarded. The polymeric oil was dried in vacuum to yield 44 g (88% yield) of extremely thick yellow oil. 1H NMR (300 MHz, CDCl3): δ=4.15-3.95 (2H, bm), 2.45-2.05 (2H, bm). 1.95-1.75 (1H, bm), 1.60-1.5 (5H, bm), 1.5-1.3 (I 1H, bm), 0.93 (3H, t). GPC (THF, polystyrene standards): Mn=25900; PDI=1.13. GPC (DMF, polyethyleneglycol standards): Mn=6600; PDI=1.58.
  • Following this procedure, 4 different first blocks were prepared, which are listed in TABLE 3 as Example 1-1 to 1-4.
  • TABLE 3
    Molecular
    weight
    Example Identification Composition (g/mol)
    1-1 nBA1tBA1_20k n-butyl acrylate-co-t-butyl 20,000
    acrylate 50/50 mol-%
    1-2 nDiBA1tBA1_20k N,N-di-n-butyl acrylamide- 20,000
    co-t-butyl acrylate 50/50
    mol-%
    1-3 nBA1tBA1_50k n-butyl acrylate-co-t-butyl 50,000
    acrylate 50/50 mol-%
    1-4 nDiBA1tBA1_50k N,N-di-n-butyl acrylamide- 50,000
    co-t-butyl acrylate 50/50
    mol-%
  • Synthesis of Poly[(n-butyl acrylate-co-t-butyl acrylate)-b-(N,N-dimethylacrylamide-co-glycidyl methacrylate)]
  • Theoretical Mn=20,000 1st block and Mn=5000 2nd block at 80% con. A solution of poly(n-butyl acrylate-co-t-butyl acrylate) terminated with the CTA (2.53 ml, 40 wt % in DMF) and a solution of AMVN (48.1 μl, 0.00736 mmol, 4 wt % in DMF) were combined manually. The mixture was then purged with Ar for 20 minutes. While stirring at room temperature, N,N-dimethylacrylamide (27.5 μl, 0.267 mmol) and a solution of glycidyl methacrylate (14.3 μl, 0.0296 mmol, 30 wt % in DMF) were added. The solution temperature was then raised to 55° C. over 30 minutes while stirring. At this time, N,N-dimethylacrylamide (10.3 μl, 0.100 mmol) and a solution of glycidyl methacrylate (5.4 μl, 0.0111 mmol, 30 wt % in DMF) were added via a robot. Every 10 minutes for the next 4 hours N,N-dimethylacrylamide (10.3 μl, 0.100 mmol) and a solution of glycidyl methacrylate (5.4 μl, 0.0111 mmol, 30 wt % in DMF) were added while the solution stirred under Ar at 55° C. After all additions had been completed, the solution was stirred for an additional 2 hours under Ar at 55° C. and then cooled to room temperature. The crude polymer was dissolved in 2 ml acetone and precipitated into 30 ml water. The resulting mixture was centrifuged at 1000 rpm for 60 minutes and the upper water layer then removed. The polymeric powder was washed with an additional 10 ml of water, centrifuged, and the water layer removed. The resulting wet powder was dried under vacuum at 30° C. to give a viscous liquid. Subsequent lyophilization provided 1.19 g (92% yield) of a sticky solid. GPC (DMF, polyethyleneglycol standards): Mn=8500; PDI=2.10.
  • Similar procedures were used to make block copolymers of various length and chemical compositions which are reported in the following tables, TABLES 4 and 5.
  • TABLE 4
    Library: Plate1 (ID: 100436) Unit: mg
    Row Col nDiBA1tBA1 20k nDiBA1tBA1 50k DMF THF AMVN GMA DMA
    A 1 1065.7 0.0 754.2 707.3 2.0 45.8 287.3
    A 2 915.9 0.0 709.1 665.0 1.7 78.7 493.8
    A 3 714.9 0.0 648.6 608.2 1.3 122.8 770.8
    A 4 1065.7 0.0 754.2 707.3 2.0 45.8 287.3
    A 5 915.9 0.0 709.1 665.0 1.7 78.7 493.8
    A 6 714.9 0.0 648.6 608.2 1.3 122.8 770.8
    B 1 982.0 0.0 810.5 760.1 1.8 116.8 190.1
    B 2 798.9 0.0 806.5 756.3 1.5 190.1 309.2
    B 3 581.8 0.0 801.7 751.8 1.1 276.8 450.4
    B 4 982.0 0.0 810.5 760.1 1.8 116.8 190.1
    B 5 798.9 0.0 806.5 756.3 1.5 190.1 309.2
    B 6 581.8 0.0 801.7 751.8 1.1 276.8 450.4
    C 1 0.0 897.8 622.9 584.1 0.7 38.6 242.0
    C 2 0.0 770.4 585.8 549.3 0.6 66.2 415.3
    C 3 0.0 600.1 536.1 502.7 0.4 103.1 647.0
    C 4 0.0 897.8 622.9 584.1 0.7 38.6 242.0
    C 5 0.0 770.4 585.8 549.3 0.6 66.2 415.3
    C 6 0.0 600.1 536.1 502.7 0.4 103.1 647.0
    D 1 0.0 826.5 670.8 629.0 0.6 98.3 160.0
    D 2 0.0 671.1 668.2 626.7 0.5 159.7 259.8
    D 3 0.0 487.7 665.3 623.9 0.4 232.1 377.6
    D 4 0.0 826.5 670.8 629.0 0.6 98.3 160.0
    D 5 0.0 671.1 668.2 626.7 0.5 159.7 259.8
    D 6 0.0 487.7 665.3 623.9 0.4 232.1 377.6
    General Design and Variations from Example(mol:mol ratios)
    Starting Rows A, B = 20 k 1:1 N,N-di-n-Butyl Acrylamide:t-Butyl Acylate
    Block Rows C, D = 50 k 1:1 N,N-di-n-Butyl Acrylamide:t-Butyl Acylate
    (45.5 wt % solns):
    Initiator: AMVN
    Temperature: 60 C.
    2nd Block Compostion: Rows A, C = 1:9 GMA:DMA
    Rows B, D = 3:7 GMA:DMA
    Block Target Mn: A1, B1, A4, B4 = 5k
    A2, B2, A5, B5 = 10k
    A3, B3, A6, B6 = 20k
    C1, D1, C4, D4 = 12.5k
    C2, D2, C5, D5 = 25k
    C3, D3, C6, D6 = 50k
    2nd Block Method: Columns 1, 2, 3 = Batch Addition
    Columns 4, 5, 6 = Spot Addition
  • TABLE 5
    Library: Plate1 (ID: 100369) Unit: mg
    Row Col GMA DMF nBA1tBA1 20k DMA AIBN
    A 1 39.8 1566.0 963.2 249.2 1.2
    A 2 72.5 1458.0 842.7 454.2 1.0
    A 3 116.8 1311.6 679.3 732.2 0.8
    A 4 39.8 1566.0 963.2 249.2 1.2
    A 5 72.5 1458.0 842.7 454.2 1.0
    A 6 116.8 1311.6 679.3 732.2 0.8
    B 1 74.2 1604.6 935.9 206.6 1.2
    B 2 132.1 1532.2 800.2 368.0 1.0
    B 3 206.6 1439.1 625.7 575.5 0.8
    B 4 74.2 1604.6 935.9 206.6 1.2
    B 5 132.1 1532.2 800.2 368.0 1.0
    B 6 206.6 1439.1 625.7 575.5 0.8
    General Design (mol:mol ratios)
    Starting Block: 20 k 1:1 n-Butyl Acrylate:t-Butyl Acylate
    Initiator: AIBN
    Temperature: 65 C.
    2nd Block Compostion: Row A = 1:9 GMA:DMA
    Row B = 2:8 GMA:DMA
    2nd Block Target Mn: Columns 1, 4 = 5k
    Columns 2, 5 = 10k
    Columns 3, 6 = 20k
    2nd Block Method: Columns 1, 2, 3 = Batch Addition
    Columns 4, 5, 6 = Spot Addition
  • General Procedure for the Synthesis of Core/Shell Crosslinked Polyallylamine Particles:
  • Preparation of polyallylamine (PAA) solution: Polyallylamine hydrochloride (Mw 15,000) was dissolved in water, and NaOH was added to neutralize 25 mol % of hydrochloride. The concentration of polyallyamine hydrochloride in solution was 33 wt. %.
  • Preparation of diblock copolymer solution: diblock copolymer was dissolved in toluene at 5 wt. %.
  • Preparation of core/shell particles: To 15 ml glass reactor was charged PAA solution, diblock copolymer solution, and toluene, and some typical solution compositions as shown in Tables 4-9. The mixture was emulsified with an Ultra-Turrax for 30 seconds and a magnetic stir bar was put into the suspension. The suspension was stirred and heated at 60° C. for 30 minutes and epichlorohydrin (10 mol % based on amine groups) was added. The suspension was further stirred at 60° C. for 8 hours and then cooled to room temperature.
  • Purification of core/shell particles: To the reaction mixture above, methanol (10 mL) was added and white particles precipitated out. The mixture was shaken for 30 minutes and centrifuged. The white particles separated from supernatant solution and collected. The white particles were further washed with methanol (10 mL×2) and water (10 mL×3) by repeating the same shake/centrifuge procedure. Finally the particles were freeze-dried for three days.
  • Example 2 Synthesis of 1,3-Diaminopropane/Epichlorohydrin Crosslinked Beads (Referred to Herein as: Bead-Pi-4-s)
  • The reaction vessel used was a 3-liter, three necked round bottom flask with four side baffles, equipped with an oil heating bath, cold-water reflux condenser, and mechanical stirrer with a 3 inch propeller. To this reaction vessel is introduced a solution of 1,3-diaminopropane (90.2 g, 1.21 mole) dissolved in 90.2 g of water, surfactant (branched dodecylbenzene sulfonic acid sodium salt, 6.4 g dissolved in 100 g of water), and 1 Kg of toluene. This initial charge is agitated to 600 rpm for 2 minutes and then lowered to 300 rpm for 10 minutes before the first addition of epichlorohydrin. This speed is maintained through out the experiment. The solution was heated to 80° C. and maintained at this temperature throughout the experiment.
  • Into a separate vessel, a 40 mass % solution of epichlorohydrin in toluene was prepared. Using a syringe pump, 1.2 equivalents of epichlorohydrin (134.7 g, (1.45 mole)) was added over a 3 hour period. The reaction was continued for an additional 2 hours before adding 0.75 equivalents of sodium hydroxide (36.5 g (0.91 mole)) in a 40 weight % solution. The sodium hydroxide solution was added to the reaction via a syringe pump over a 2.5-hour period. The reaction was maintained at 80° C. for a further 8 hours. The beads were purified by removing the toluene, washing with 1000 ml of acetone, followed by methanol, and then a 20% solution of NaOH (to remove the surfactant), and twice more with deionized water. The beads were freeze dried for 3 days to give a fine white powder weighing at 160 g (92% yield), and having a mean diameter of 93 μm.
  • Synthesis of 1,3-Diaminopropane/Epichlorohydrin Crosslinked Beads (Referred to Herein as: Bead-Pi-3-s)
  • The procedure described above was used with 1 equivalent of epichlorohydrin.
  • Synthesis of Water Swollen Crosslinked Beads Prepared with 1,3-Diaminopropane/Epichlorohydrin in the Presence of Surfactant (Referred to Herein as: Bead-Pi-5-s)
  • The procedure described above for the preparation of beads from 1,3-diaminopropane/epichlorohydrin was reproduced exactly up to stage 2. After the reaction flask had cooled to room temperature, the stirring was stopped. The beads settle to the bottom of the flask. The clear toluene layer was decanted from the reaction and replaced by fresh toluene to remove unreacted epichlorohydrin. This procedure was repeated 4 times and washing with a total of 3000 ml of toluene. Through out this process the beads were not allowed to dry out. The total weight of the solution was made to 756 g by adding toluene to give a 21 wt-% solution of bead suspended in toluene.
  • Example 3 Preparation of Ethyl Cellulose Shell/1,3 Di-Amino Propane Epichlorohydrine Crosslinked Core Particle
  • The beads obtained from Example 2 are spray-coated with an ethyl cellulose polymer shell using a Wurster fluid bed coater 2″-4″/6″ Portable Unit. The fluidized bed unit is operated so that an average 5 microns thick coating is deposited on the core particles, using a 30 wt-% solid aqueous emulsion (Aquacoat® ECD, FMC corp.).
  • Example 4 Binding Capacity in a Digestion Mimic
  • This procedure was used to mimic the conditions of use of a phosphate binder drug and measure the binding characteristics of the polymer for phosphate (target solute) in the presence of other metabolites (competing solutes). A liquid meal was prepared and the meal was artificially digested in the presence of pepsin and pancreatic juice. The sequence of addition of enzymes and the pH profile were controlled so that the digestion process was simulated down to the jejunum level. An aliquot of the digested meal mimic is centrifuged and the supernatant assayed for phosphate.
  • An aliquot of dried resin of weight P(gr), was mixed under gentle agitation with a fixed volume, V(ml), of a meal digest solution with a phosphate ion concentration of Cstart(mM). After resin equilibration, the solution was decanted by centrifugation and the supernatant analyzed for residual phosphate concentration by ionic chromatography, Ceq(mM). The binding capacity was calculated as BC (mmol/gr)=V.(Cstart−Ceq)/P.
  • A. Core/Shell Crosslinked Polyallylamine Particles
  • Procedures described in Example 1 were implemented in a library format of 4×6 reactors, where the nature of the block copolymer was varied from well to well, as indicated in Tables 6-9. Entries correspond to the weight of chemicals used in each reaction well and to the phosphate binding capacity measured in the meal digest fluid. A Selectivity Index (SI) was computed to measure the phosphate binding relative to the core material (i.e. crosslinked polyallylamine, Renagel). When SI was greater than 1, the core-shell material bound more phosphate than the corresponding core polymer on a weight basis. The SI values for the polymers are included in Tables 6-9.
  • Results are shown in Tables 6-9. Results collated in this series of examples show that the core-shell particles of the invention display higher binding for phosphate over bare, non-encapsulated particles in simulated fluid representative of the real conditions of use. Some of the best performing core-shell materials are then assessed in binding phosphate in the ex-vivo aspirates from human intestinal content.
  • TABLE 6
    Library 100411
    Library: Plate1 Unit: ul
    Row Col toluene di-block s PAA s ECH di-block Pstart (mM) Peq (mM) BC (mmol/gr) SI(—)
    1 1 281 1860 750 22.6 369_A1 7.6 2.98 1.85 1.09
    1 2 281 1860 750 22.6 369_A2 7.6 2.41 2.08 1.22
    1 3 281 1860 750 22.6 369_A4 7.6 2.99 1.84 1.08
    1 4 281 1860 750 22.6 369_A5 7.6 2.85 1.90 1.12
    2 1 281 1860 750 22.6 369_B1 7.6 3.15 1.78 1.05
    2 2 281 1860 750 22.6 369_B2 7.6 2.35 2.10 1.23
    2 3 281 1860 750 22.6 369_B4 7.6 2.76 1.94 1.14
    2 4 281 1860 750 22.6 369_B5 7.6 2.86 1.90 1.12
    Polyallylamine core 7.6 3.35 1.70 1.00
    Diblock is dispensed as a 5 wt-% solution in toluene
  • TABLE 7
    Library: Plate1 (ID: 100482) Unit: mg
    Block copolymers
    Row Col 436 B4 436 B5 436 B6 436 D4 436 D5 436 D6 Pstart m (M) Peq (mM) BC (mmol/gr) SI (—)
    1 1 81.00 0.00 0.00 0.00 0.00 0.00
    1 2 0.00 81.00 0.00 0.00 0.00 0.00 13.41 6.32 2.84 1.02
    1 3 0.00 0.00 81.00 0.00 0.00 0.00 13.41 6.05 2.94 1.06
    1 4 0.00 0.00 0.00 81.00 0.00 0.00 13.41 5.53 3.16 1.14
    1 5 0.00 0.00 0.00 0.00 81.00 0.00 13.41 6.33 2.83 1.02
    1 6 0.00 0.00 0.00 0.00 0.00 81.00 13.41 4.57 3.54 1.28
    2 1 40.50 0.00 0.00 0.00 0.00 0.00 13.41 6.66 2.70 0.97
    2 2 0.00 40.50 0.00 0.00 0.00 0.00 13.41 5.55 3.15 1.13
    2 3 0.00 0.00 40.50 0.00 0.00 0.00 13.41 5.36 3.22 1.16
    2 4 0.00 0.00 0.00 40.50 0.00 0.00 13.41 4.98 3.37 1.22
    2 5 0.00 0.00 0.00 0.00 40.50 0.00 13.41 4.82 3.44 1.24
    2 6 0.00 0.00 0.00 0.00 0.00 40.50 13.41 3.96 3.78 1.36
    3 1 81.00 0.00 0.00 0.00 0.00 0.00 13.41 5.70 3.08 1.11
    3 2 0.00 81.00 0.00 0.00 0.00 0.00 13.41 7.09 2.53 0.91
    3 3 0.00 0.00 81.00 0.00 0.00 0.00 13.41 5.72 3.08 1.11
    3 4 0.00 0.00 0.00 81.00 0.00 0.00 13.41 6.57 2.74 0.99
    3 5 0.00 0.00 0.00 0.00 81.00 0.00 13.41 6.40 2.80 1.01
    3 6 0.00 0.00 0.00 0.00 0.00 81.00 13.41 6.54 2.75 0.99
    4 1 40.50 0.00 0.00 0.00 0.00 0.00 13.41 5.36 3.22 1.16
    4 2 0.00 40.50 0.00 0.00 0.00 0.00 13.41 6.07 2.94 1.06
    4 3 0.00 0.00 40.50 0.00 0.00 0.00 13.41 5.51 3.16 1.14
    4 4 0.00 0.00 0.00 40.50 0.00 0.00 13.41 4.21 3.68 1.33
    4 5 0.00 0.00 0.00 0.00 40.50 0.00 13.41 4.96 3.38 1.22
    4 6 0.00 0.00 0.00 0.00 0.00 40.50 13.41 4.58 3.53 1.27
    Polyallylamine 13.41 6.48 2.77 1.00
    core
    Constant reactor composition (mg)
    toluene PAA H2O NaOH EPH
    1768.95 270.00 511.16 28.84 40.05
    Row 1 & 2: 30 sec. sonication time
    Row 3 & 4: 90 sec. sonication time
  • TABLE 8
    Library Sample Block Copolymer BC (mmol/gr) IC (—)
    100516 100516 A1 100436 A1 3.02 1.25
    100516 100516 A2 100436 A2 3.44 1.43
    100516 100516 A3 100436 A3 3.33 1.38
    100516 100516 A4 100436 A4 3.01 1.25
    100516 100516 A5 100436 A5 3.29 1.37
    100516 100516 A6 100436 A6 3.52 1.46
    100516 100516 B1 100436 B1 3.30 1.37
    100516 100516 B2 100436 B2 3.60 1.49
    100516 100516 B3 100436 B3 3.38 1.40
    100516 100516 B4 100436 B4 3.52 1.46
    100516 100516 B5 100436 B5 3.74 1.55
    100516 100516 B6 100436 B6 3.32 1.38
    100516 100516 C1 100436 C1 3.89 1.61
    100516 100516 C2 100436 C2 3.54 1.47
    100516 100516 C3 100436 C3 2.75 1.14
    100516 100516 C4 100436 C4 3.57 1.48
    100516 100516 C5 100436 C5 3.53 1.47
    100516 100516 C6 100436 C6 2.64 1.09
    100516 100516 D1 100436 D1 3.78 1.57
    100516 100516 D2 100436 D2 3.57 1.48
    100516 100516 D3 100436 D3 3.12 1.29
    100516 100516 D4 100436 D4 3.40 1.41
    100516 100516 D5 100436 D5 3.75 1.55
    Polyallylamine core 2.41 1.00
    Constant reactor composition (mg)
    toluene PAA H2O NaOH EPH Block cop.
    1768.95 270.00 511.16 28.84 40.05 40.05
    30 sec. sonication time
    Library 100517 is identical to 100516 with the exception that the beads
    were further treated with HCl 1M for 6 hrs @60° C. to deprotect the
    terbutylacrylate groups into acrylic acid groups.
  • TABLE 9
    Library Sample Block Copolymer BC (mmol/gr) IC (—)
    100517 100517 A1 100436 A1 3.04 1.26
    100517 100517 A2 100436 A2 3.30 1.37
    100517 100517 A3 100436 A3 3.26 1.35
    100517 100517 A4 100436 A4 3.35 1.39
    100517 100517 A5 100436 A5 2.86 1.18
    100517 100517 B1 100436 B1 3.22 1.33
    100517 100517 B2 100436 B2 3.60 1.49
    100517 100517 B3 100436 B3 3.64 1.51
    100517 100517 B4 100436 B4 3.58 1.48
    100517 100517 B5 100436 B5 3.82 1.58
    100517 100517 B6 100436 B6 3.62 1.50
    100517 100517 C1 100436 C1 3.52 1.46
    100517 100517 C2 100436 C2 3.37 1.39
    100517 100517 C3 100436 C3 2.86 1.18
    100517 100517 C4 100436 C4 3.24 1.34
    100517 100517 C5 100436 C5 3.34 1.38
    100517 100517 C6 100436 C6 2.22 0.92
    100517 100517 D1 100436 D1 3.24 1.34
    100517 100517 D2 100436 D2 3.17 1.31
    100517 100517 D3 100436 D3 3.21 1.33
    100517 100517 D4 100436 D4 3.32 1.38
    100517 100517 D5 100436 D5 3.02 1.25
    Polyallyamine core 2.42 1.00
    Constant reactor composition (mg)
    toluene PAA H2O NaOH EPH Block cop.
    1768.95 270.00 511.16 28.84 40.05 40.05
    30 sec. sonication time
    Library 100517 is identical to 100516 with the exception that the beads
    were further treated with HCl 1M for 6 hrs @60° C. to deprotect the
    terbutylacrylate groups into acrylic acid groups.
  • B. Core/Shell Crosslinked 1,3-Diaminopropane/Epichlorohydrine Particles
  • Procedures described in Example 2 were implemented in a library format of 4×6 reactors, where the nature of the polymer was varied from well to well, as indicated in Tables 1′-18. Entries in the Tables correspond to the weight of chemicals used in each reaction well, and to the phosphate binding capacity measured in the meal digest fluid. A Selectivity Index (SI) was computed as described above. The SI values for the polymers are included in Tables 11-18.
  • Each example comprised a library of 22 core-shell materials and one core material taken as a reference. The core materials are beads prepared from crosslinked 1,3-diaminopropane/epichlorohydrine as shown in Example 2 (bead 4-s, bead 3-s, and bead 5-s). They were used either as a dry powder (bead 4-s, bead 3-s) or as a slurry in toluene (bead 5-s). The core-shell particles were prepared in semi-continuous reactors arranged in a 4×6 library format. Each reactor had a 3 ml volume, was magnetically stirred, and temperature-controlled. In a typical procedure, the beads were first dispensed, followed by the addition of the selected solvent under magnetic agitation. The reaction temperature was set to 60° C. The shell materials were then robotically dispensed for 4 hours and the 24 reactions kept another 12 hours at the set temperature. The library was then cooled down to ambient temperature and the content of the reactors transferred to 15 ml vials. The core-shell beads were then washed repeatedly with a fresh volume of the same solvent used during the shell coupling reaction, then with isopropanol, and finally with de-ionized water. The particles were finally lyophilized.
  • The chemical structures of the shell materials used are shown in Table 10.
  • TABLE 10
    Label Name CAS # Structure MW (g/mol)
    Shell-AH-1 POLY(METHYLVINYL ETHER-ALT- MALEIC ANHYDRIDE)
    Figure US20090148533A1-20090611-C00003
    MW ~ 20,000
    Shell-AH-2 POLY(METHYLVINYL ETHER-ALT- MALEIC ANHYDRIDE)
    Figure US20090148533A1-20090611-C00004
    MW ~ 50,000
    Shell-AH-3 POLY(METHYLVINYL ETHER-ALT- MALEIC ANHYDRIDE) 9011-16-9
    Figure US20090148533A1-20090611-C00005
    Mn. ~ 80,000 Mw. ~ 216,000
    Shell-AH-4 POLY(STYRENE-MALEIC MW = 1600
    ANHYDRIDE) 50:50 (molar)
    Shell-AH-5 POLY(STYRENE-MALEIC MW = 1900
    ANHYDRIDE) 75:25 (molar)
    Shell-AH-6 POLY(STYRENE-co- 26762-29-8 Mn = 1600
    MALEIC
    ANHYDRIDE), CUMENE
    TERMINATED
    Shell-AH-7 POLY(STYRENE-co- 26762-29-8 Mn = 1700
    MALEIC
    ANHYDRIDE), CUMENE
    TERMINATED
    Shell-AH-8 POLY(STYRENE-co- 160611-46-1 Mn = 2300
    MALEIC FW = 658.8
    ANHYDRIDE), PARTIAL
    ISOCTYL
    ESTER, CUMENE
    TERMINATED
    Shell-AH-9 POLY(STYRENE-co- 160611-50-7 Av. Mn = 2500
    MALEIC
    ANHYDRIDE), PARTIAL 2-
    BUTOXYETHYLESTER,
    CUMENE
    TERMINATED
    Shell-AH-10 POLY(ETHYLENE-co- 41171-14-6 /
    ETHYL
    ACRYLATE-co-MALEIC
    ANHYDRIDE)
    Shell-AH-11 POLY(STYRENE-co- 160611-48-3 Mn ~ 1900
    MALEIC
    ANHYDRIDE), PARTIAL
    PROPYL
    ESTER, CUMENE
    TERMINATED
    Shell-AH-12 POLYETHYLENE-graft- 106343-08-2 FW ~ 154.2
    MALEIC
    ANHYDRIDE
    Shell-AH-13 POLYISOPRENE-graft- 139948-75-7 FW = 234.3
    MALEIC Mn ~ 25000
    ANHYDRIDE
    Shell-AH-14 POLY(ETHYLENE-co- 64652-60-4 FW = 268.3
    BUTYL
    ACRYLATE-co-MALEIC
    ANHYDRIDE)
    Shell-Cl-1 2-CHLOROETHANE- SULFONIC ACID SODIUM SALT 15484-44-3
    Figure US20090148533A1-20090611-C00006
    166.56
    Shell-Cl-2 3-CHLORO-2- HYDROXYPROPANE- SULFONIC ACID SODIUM SALT 126-83-0
    Figure US20090148533A1-20090611-C00007
    196.59
    Shell-Mc-1 DIETHYLENE GLYCOL DIACRYLATE 4074-88-8
    Figure US20090148533A1-20090611-C00008
    214.22
    Shell-Mc-2 POLY(ETHYLENE GLYCOL) DIACRYLATE 26570-49-8
    Figure US20090148533A1-20090611-C00009
    Mn. ~ 700
    Shell-Mc-3 POLY(ETHYLENE-co- 51541-08-3 FW = 256.3
    METHACRYLATE-co-
    GLYCIDYL
    METHACRYLATE)
    Shell-EP-1 2-(3,4- EPOXYCYCLOHEXYL)- ETHYL- TRIETHOXYSILANE
    Figure US20090148533A1-20090611-C00010
    288.5
    Shell-EP-2   Shell-EP-3     Shell-EP-4     Shell-EP-5     Shell-EP-6 POLY(ETHYL GLYCOL) DIGLYCIDYL ETHER POLY(ETHYL GLYCOL) (200) DIGLYCIDYL ETHER POLY(ETHYL GLYCOL) (400) DIGLYCIDYL ETHER POLY(ETHYL GLYCOL) (600) DIGLYCIDYL ETHER POLY(ETHYL GLYCOL) (1000) DIGLYCIDYL ETHER 26403-72-5   26403-72-5     26403-72-5     26403-72-5     26403-72-5
    Figure US20090148533A1-20090611-C00011
    526.6   200     400     600     1000
    Shell-EP-7 1,3-BUTADIENE DIEPOXIDE 1464-53-5
    Figure US20090148533A1-20090611-C00012
    86.09
    Shell-EP-8 3-(1H,1H,7H- DODECAFLUORO- HEPTYLOXY)- 1,2-EPOXYPROPANE 799-34-8
    Figure US20090148533A1-20090611-C00013
    388.15
    Shell-EP-9 GLYCIDYL 4-NONYLPHENYL ETHER 6178-32-1
    Figure US20090148533A1-20090611-C00014
    276.42
    Shell-EP-10 POLY(PROPYLENE GLYCOL) DIGLYCIDYL ETHER 26142-30-3
    Figure US20090148533A1-20090611-C00015
    640
    Shell-EP-11 GLYCIDYL HEXADECYL ETHER 15965-99-8
    Figure US20090148533A1-20090611-C00016
    298.51
    Shell-EP- 12bis 2-[(4- NITROPHENOXY) METHYL] OXIRANE 5255-75-4
    Figure US20090148533A1-20090611-C00017
    195.18
    Shell-EP-12 POLY(BISPHENOL A-co- 25036-25-3 FW = 487.0
    EPICHLOROHYDRIN), Mn ~ 355
    GLYCICYL
    END-CAPPED
    Shell-EP-13 POLY(BISPHENOL A-co- FW = 487.0
    EPICHLOROHYDRIN), Mn ~ 1075
    GLYCICYL
    END-CAPPED
    Shell-EP-14 POLY(BISPHENOL A-co- Mn ~ 1750
    EPICHLOROHYDRIN),
    GLYCICYL
    END-CAPPED
    Shell-EP-15 POLY(BISPHENOL A-co- /
    EPICHLOROHYDRIN),
    GLYCICYL
    END-CAPPED
    Shell-EP-16 POLY(o-CRESYL 29690-82-2 FW = 194.2
    GLYCIDYL ETHER)-co- Mn ~ 540
    FORMALDEHYDE)
    Shell-EP-17 POLY(o-CRESYL 29690-82-3 FW = 194.2
    GLYCIDYL ETHER)-co- Mn ~ 1270
    FORMALDEHYDE)
    Shell-EP-18 POLY(ETHYLENE-co- 26061-90-5 FW = 170.2
    GLYCIDYL
    METHACRYLATE)
    Shell-EP-19 BISPHENOL DIGLYCIDYL 1675-54-3
    ETHER
    Shell-EP-20 POLY 130167-23-6 FW = 282.5
    (DIMETHYLSILOXANE) EW ~ 490
    DIGLYCIDYL
    TERMINATED
    Shell-EP-21 POLY[(PHENYL / FW = 180.2
    GLYCIDYL ETHER)- Mn ~ 345
    co-FORMALDEHYDE]
    Shell-EP-22 POLY[(PHENYL 28064-14-4 FW = 180.2
    GLYCIDYL ETHER)- Mn ~ 570
    co-FORMALDEHYDE]
    Shell-EP-23 POLY[(PHENYL 119345-05-0 FW = 286.4
    GLYCIDYL ETHER)- Mn ~ 490
    co-DICYCLOPENTADIENE]
    Shell-EP-24 POLY 26587-37-1
    (EPICHLOROHYDRIN-co
    ETHYLENE OXIDE-co-
    ALLY
    GLYCIDYL ETHER
    Shell-EP-25 CASTOR OIL GLYCIDYL 74398-71-3
    ETHER
    Shell-EP-26 TETRA- /
    PHENYLOLETHANE
    GLYCIDYL ETHER
    Shell-EP-27 EPON RESINS-828 /
  • Results are shown in Tables 11-18. Results collated in this series of example show that the core-shell particles of the invention display higher rate of binding for phosphate over bare, non-encapsulated particles in simulated fluid representative of the real conditions of use.
  • TABLE 11
    Shell- Shell- Shell- Shell- bead- bead- bead- BC SI
    library ID row column NaOH EP-10 EP-12 EP-16 Mc-3 pi-3 pi-4 pi-5 toluene water (mmol/gr) (—)
    100433 A 1 0.00 1.25 23.75 0.41 0.76
    100433 A 2 0.00 1.25 23.75 0.46 0.85
    100433 A 3 0.00 1.25 23.75 0.43 0.81
    100433 A 4 0.00 1.25 23.75 0.40 0.74
    100433 A 5 0.00 1.25 23.75 0.40 0.75
    100433 A 6 0.00 1.25 23.75 0.48 0.90
    100433 B 1 0.00 1.25 23.75 0.50 0.93
    100433 B 2 0.00 1.25 23.75 0.51 0.94
    100433 B 3 0.00 1.25 23.75 0.58 1.07
    100433 B 4 0.00 1.25 23.75 0.64 1.19
    100433 B 5 0.00 1.25 23.75 0.38 0.70
    100433 B 6 0.00 1.25 23.75 0.35 0.66
    100433 C 1 0.10 1.25 23.66 0.29 0.55
    100433 C 2 0.10 1.25 23.66 0.60 1.12
    100433 C 3 0.10 1.25 23.66 0.49 0.91
    100433 C 4 0.10 1.25 23.66 0.70 1.30
    100433 C 5 0.10 1.25 23.66 0.44 0.82
    100433 C 6 25.00 0.54 1.00
    100433 D 1 1.25 23.75 0.56 1.03
    100433 D 2 1.25 23.75 0.63 1.18
    100433 D 3 1.25 23.75 0.50 0.94
    100433 D 4 1.25 23.75 0.57 1.06
    100433 D 5 1.25 23.75 0.43 0.80
    100461 A 1 24.00 120.00 2256.00 1.47 1.08
    100461 A 2 56.40 141.00 2622.60 1.46 1.07
    100461 A 3 95.88 159.80 2940.32 1.45 1.07
    100461 A 4 124.00 155.00 2821.00 1.48 1.09
    100461 A 5 108.60 108.60 1954.80 1.40 1.03
    100461 B 1 32.92 164.60 3094.48 1.26 0.92
    100461 B 2 59.04 147.60 2745.36 1.51 1.11
    100461 B 3 96.24 160.40 2951.36 1.48 1.09
    100461 B 4 129.12 161.40 2937.48 1.46 1.07
    100461 B 5 136.10 136.10 2449.80 1.57 1.15
    100461 C 1 33.18 165.90 3118.92 1.38 1.02
    100461 C 2 54.20 135.50 2520.30 1.39 1.02
    100461 C 3 90.36 150.60 2771.04 1.53 1.13
    100461 C 4 93.36 116.70 2123.94 1.35 1.00
    100461 C 5 148.70 148.70 2676.60 1.52 1.12
    100461 C 6 165.10 1.36 1.00
    100461 D 1 32.56 162.80 3060.64 1.37 1.01
    100461 D 2 75.16 187.90 3494.94 1.24 0.91
    100461 D 3 65.94 109.90 2022.16 1.44 1.06
    100461 D 4 100.08 125.10 2276.82 1.49 1.10
    100461 D 5 166.30 166.30 2993.40 1.47 1.08
    100462 A 1 24.21 121.02 2275.23 1.51 1.13
    100462 A 2 44.65 111.62 2076.04 1.54 1.15
    100462 A 3 64.15 106.91 1967.16 1.45 1.08
    100462 A 4 76.94 96.18 1750.48 1.46 1.09
    100462 A 5 109.49 109.49 1970.89 1.53 1.14
    100462 B 1 22.44 112.20 2109.42 1.49 1.11
    100462 B 2 45.46 113.65 2113.93 1.41 1.05
    100462 B 3 67.79 112.98 2078.83 1.55 1.16
    100462 B 4 89.96 112.46 2046.68 1.55 1.16
    100462 B 5 102.12 102.12 1838.21 1.51 1.12
    100462 C 1 22.22 111.09 2088.49 1.69 1.26
    100462 C 2 42.97 107.44 1998.31 1.76 1.31
    100462 C 3 59.03 98.39 1810.28 1.74 1.30
    100462 C 4 86.34 107.92 1964.13 1.59 1.18
    100462 C 5 108.15 108.15 1946.70 1.48 1.10
    100462 C 6 100.30 377.30 1.34 1.00
    100462 D 1 20.03 100.15 1882.80 1.60 1.20
    100462 D 2 38.24 95.59 1778.01 1.80 1.34
    100462 D 3 56.73 94.54 1739.57 1.75 1.31
    100462 D 4 85.36 106.70 1941.96 2.00 1.49
    100462 D 5 103.19 103.19 1857.49 2.06 1.54
  • TABLE 12
    Shell- Shell- Shell- Shell- bead- ethyl BC SI
    library ID row column AH-11 AH-9 EP-8 IC-1 pi-5 acetate methanol toluene water (mmol/gr) (—)
    100468 A 1 31.70 158.50 2979.80 1.48 0.96
    100468 A 2 76.28 190.70 3547.02 1.63 1.06
    100468 A 3 106.20 177.00 3256.80 1.56 1.01
    100468 A 4 133.20 166.50 3030.30 1.50 0.98
    100468 A 5 123.40 123.40 2221.20 1.53 0.99
    100468 B 1 28.06 140.30 2637.64 1.70 1.10
    100468 B 2 52.48 131.20 2440.32 1.60 1.04
    100468 B 3 84.48 140.80 2590.72 1.70 1.10
    100468 B 4 106.00 132.50 2411.50 1.73 1.12
    100468 B 5 146.40 146.40 2635.20 1.70 1.11
    100468 C 1 28.96 144.80 2722.24 1.53 0.99
    100468 C 2 50.20 125.50 2334.30 1.45 0.94
    100468 C 3 93.48 155.80 2866.72 1.48 0.96
    100468 C 4 140.24 175.30 3190.46 1.37 0.89
    100468 C 5 188.80 188.80 3398.40 1.19 0.78
    100468 C 6 221.10 1.54 1.00
    100468 D 1 41.38 206.90 3889.72 1.44 0.94
    100468 D 2 61.84 154.60 2875.56 1.49 0.97
    100468 D 3 109.62 182.70 3361.68 1.46 0.95
    100468 D 4 117.04 146.30 2662.66 1.45 0.94
    100468 D 5 148.20 148.20 2667.60 1.46 0.95
  • TABLE 13
    Shell- Shell- Shell- Shell- Shell- bead- ethyl BC SI
    library ID row column EP-1 EP-10 EP-12bis EP-13 Mc-2 pi-5 acetate toluene (mmol/gr) (—)
    100473 A 1 94.02 156.70 2883.28 1.68 1.10
    100473 A 2 89.82 149.70 2754.48 1.52 0.99
    100473 A 3 114.12 190.20 3499.68 1.57 1.02
    100473 A 4 95.76 159.60 2936.64 1.47 0.96
    100473 A 5 81.12 135.20 2487.68 1.47 0.96
    100473 B 1 98.52 164.20 3021.28 1.49 0.97
    100473 B 2 98.76 164.60 3028.64 1.44 0.94
    100473 B 3 109.80 183.00 3367.20 1.37 0.89
    100473 B 4 92.70 154.50 2842.80 1.41 0.92
    100473 B 5 114.24 190.40 3503.36 1.46 0.96
    100473 C 1 90.18 150.30 2765.52 1.46 0.95
    100473 C 2 90.00 150.00 2760.00 1.43 0.94
    100473 C 3 82.74 137.90 2537.36 1.41 0.92
    100473 C 4 99.12 165.20 3039.68 1.35 0.88
    100473 C 5 106.32 177.20 3260.48 1.36 0.89
    100473 C 6 212.40 1.53 1.00
    100473 D 1 90.84 151.40 2785.76 1.24 0.81
    100473 D 2 100.68 167.80 3087.52 1.42 0.93
    100473 D 3 113.82 189.70 3490.48 1.45 0.95
    100473 D 4 105.36 175.60 3231.04 1.46 0.95
    100473 D 5 90.30 150.50 2769.20 1.51 0.99
    100474 A 1 90.18 150.30 2765.52 1.64 1.19
    100474 A 2 86.88 144.80 2664.32 1.42 1.03
    100474 A 3 101.94 169.90 3126.16 1.26 0.91
    100474 A 4 100.92 168.20 3094.88 1.36 0.99
    100474 A 5 94.32 157.20 2892.48 1.47 1.07
    100474 B 1 88.02 146.70 2699.28 1.36 0.98
    100474 B 2 95.70 159.50 2934.80 1.37 0.99
    100474 B 3 89.88 149.80 2756.32 1.48 1.07
    100474 B 4 109.02 181.70 3343.28 1.40 1.02
    100474 B 5 86.46 144.10 2651.44 1.43 1.04
    100474 C 1 84.60 141.00 2594.40 1.42 1.03
    100474 C 2 89.52 149.20 2745.28 1.45 1.05
    100474 C 3 84.72 141.20 2598.08 1.48 1.07
    100474 C 4 112.02 186.70 3435.28 1.44 1.04
    100474 C 5 104.58 174.30 3207.12 1.42 1.03
    100474 C 6 216.20 1.38 1.00
    100474 D 1 94.50 157.50 2898.00 1.48 1.07
    100474 D 2 110.40 184.00 3385.60 1.42 1.03
    100474 D 3 102.18 170.30 3133.52 1.72 1.25
    100474 D 4 87.84 146.40 2693.76 1.54 1.12
    100474 D 5 97.86 163.10 3001.04 1.53 1.11
    100480 A 1 29.76 148.80 2797.44 1.32 0.95
    100480 A 2 77.96 194.90 3625.14 1.18 0.85
    100480 A 3 102.24 170.40 3135.36 0.95 0.68
    100480 A 4 133.28 166.60 3032.12 0.79 0.57
    100480 A 5 143.90 143.90 2590.20 0.80 0.57
    100480 B 1 32.08 160.40 3015.52 0.99 0.71
    100480 B 2 69.20 173.00 3217.80 1.14 0.82
    100480 B 3 112.20 187.00 3440.80 1.24 0.89
    100480 B 4 130.72 163.40 2973.88 1.35 0.96
    100480 B 5 155.80 155.80 2804.40 1.12 0.80
    100480 C 1 31.16 155.80 2929.04 1.25 0.90
    100480 C 2 56.00 140.00 2604.00 1.30 0.93
    100480 C 3 95.16 158.60 2918.24 1.45 1.03
    100480 C 4 157.76 197.20 3589.04 1.56 1.12
    100480 C 5 162.60 162.60 2926.80 1.55 1.11
    100480 C 6 149.00 1.40 1.00
    100480 D 1 29.76 148.80 2797.44 1.44 1.03
    100480 D 2 73.68 184.20 3426.12 1.39 0.99
    100480 D 3 93.78 156.30 2875.92 1.39 1.00
    100480 D 4 131.36 164.20 2988.44 1.34 0.96
    100480 D 5 145.10 145.10 2611.80 1.31 0.94
  • TABLE 14
    Shell- Shell- Shell- Shell- bead- bead- ethyl BC SI
    library ID row column EP-11 EP-12 bis EP-8 EP-9 pi-4 pi-5 acetate methanol toluene (mmol/gr) (—)
    100484 A 1 3.41 170.70 3239.89 1.89 1.36
    100484 A 2 10.50 161.50 3058.00 1.78 1.29
    100484 A 3 20.14 183.10 3458.76 1.82 1.31
    100484 A 4 21.39 138.00 2600.61 1.36 0.98
    100484 A 5 32.66 163.30 3070.04 1.29 0.93
    100484 B 1 3.17 158.30 3004.53 1.85 1.33
    100484 B 2 10.22 157.20 2976.58 1.93 1.39
    100484 B 3 19.91 181.00 3419.09 1.83 1.32
    100484 B 4 25.05 161.60 3045.35 1.89 1.36
    100484 B 5 29.72 148.60 2793.68 1.91 1.38
    100484 C 1 2.99 149.50 2837.51 2.09 1.51
    100484 C 2 10.04 154.40 2923.56 1.95 1.41
    100484 C 3 19.93 181.20 3422.87 1.83 1.32
    100484 C 4 25.76 166.20 3132.04 1.80 1.30
    100484 C 5 30.60 153.00 2876.40 1.85 1.33
    100484 C 6 211.50 1.39 1.00
    100484 D 1 3.07 153.30 2909.63 1.39 1.00
    100484 D 2 12.33 189.70 3591.97 1.88 1.35
    100484 D 3 18.22 165.60 3128.18 1.76 1.27
    100484 D 4 27.27 175.90 3314.84 1.77 1.27
    100484 D 5 32.16 160.80 3023.04 1.83 1.32
    100485 A 1 3.05 152.36 2318.55 573.15 1.29 0.92
    100485 A 2 9.71 149.33 2265.81 561.77 1.03 0.73
    100485 A 3 17.53 159.33 2410.31 599.37 1.04 0.74
    100485 A 4 25.50 164.51 2481.38 618.89
    100485 A 5 35.53 177.66 2671.67 668.34 0.89 0.63
    100485 B 1 3.34 167.03 3170.31 1.39 0.98
    100485 B 2 8.54 131.44 2488.80 0.69 0.49
    100485 B 3 16.87 153.38 2897.42 1.12 0.80
    100485 B 4 23.64 152.48 2873.50 1.49 1.06
    100485 B 5 33.68 168.42 3166.30 1.55 1.10
    100485 C 1 3.06 152.78 2899.67 1.31 0.93
    100485 C 2 9.44 145.19 2749.25 1.50 1.06
    100485 C 3 16.51 150.09 2835.14 1.49 1.05
    100485 C 4 24.86 160.40 3022.70 1.42 1.01
    100485 C 5 28.96 144.82 2722.54 1.36 0.96
    100485 C 6 139.29 524.01 1.41 1.00
    100485 D 1 3.02 150.99 2865.79 1.45 1.03
    100485 D 2 10.35 159.29 3016.06 1.48 1.05
    100485 D 3 22.61 205.53 3882.41 1.02 0.73
    100485 D 4 23.91 154.29 2907.54 1.24 0.88
    100485 D 5 28.81 144.06 2708.33 0.82 0.58
  • TABLE 15
    Library: Plate1 (ID: 100500) Unit: mg
    BC
    Row Col bead-pi-4 toluene Shell-EP-12 (mmol/gr) SI (—)
    1.00 1.00 171.99 3233.41 34.40 1.31 1.26
    1.00 2.00 144.02 2678.73 57.61 0.93 0.90
    1.00 3.00 152.57 2807.20 91.54 1.15 1.10
    1.00 4.00 156.60 2850.07 125.28 0.71 0.68
    1.00 5.00 156.32 2813.83 156.32 0.78 0.75
    2.00 1.00 156.72 2946.39 31.34 1.39 1.33
    2.00 2.00 156.74 2915.44 62.70 1.61 1.54
    2.00 3.00 154.35 2840.04 92.61 2.08 1.99
    2.00 4.00 154.35 2809.17 123.48 0.53 0.50
    2.00 5.00 153.59 2764.69 153.59 0.60 0.57
    2.00 6.00 140.87 529.93 0.00 0.89 0.86
    3.00 1.00 140.18 2635.29 28.04 1.15 1.11
    3.00 2.00 148.66 2765.06 59.46 1.84 1.77
    3.00 3.00 142.44 2620.95 85.47 1.72 1.65
    3.00 4.00 149.00 2711.71 119.20 2.27 2.18
    3.00 5.00 137.05 2466.83 137.05 0.73 0.70
    3.00 6.00 153.03 575.67 0.00 1.04 1.00
    4.00 1.00 141.54 2660.95 28.31 1.24 1.19
    4.00 2.00 148.47 2761.54 59.39 1.60 1.54
    4.00 3.00 130.16 2394.91 78.09 1.17 1.12
    4.00 4.00 137.76 2507.23 110.21 1.37 1.31
    4.00 5.00 140.22 2523.91 140.22 0.96 0.93
  • TABLE 16
    Library: Plate2 (ID: 100501) Unit: mg
    BC
    Row Col bead-pi-4 toluene Shell-EP-16 (mmol/gr) SI (—)
    1.00 1.00 150.72 2833.48 30.14 0.94 0.87
    1.00 2.00 150.15 2792.79 60.06 1.22 1.12
    1.00 3.00 143.91 2648.00 86.35 1.33 1.23
    1.00 4.00 153.43 2792.35 122.74 1.81 1.67
    1.00 5.00 154.94 2788.88 154.94 1.01 0.94
    2.00 1.00 150.32 2825.98 30.06 1.00 0.93
    2.00 2.00 149.12 2773.65 59.65 1.44 1.33
    2.00 3.00 149.18 2744.99 89.51 1.93 1.78
    2.00 4.00 147.19 2678.84 117.75 1.49 1.38
    2.00 5.00 147.82 2660.74 147.82 0.92 0.85
    2.00 6.00 147.27 554.03 0.00 0.92 0.85
    3.00 1.00 140.45 2640.42 28.09 0.96 0.88
    3.00 2.00 141.39 2629.91 56.56 1.50 1.39
    3.00 3.00 140.51 2585.40 84.31 0.96 0.89
    3.00 4.00 149.00 2711.71 119.20 1.76 1.63
    3.00 5.00 131.23 2362.12 131.23 0.00
    3.00 6.00 150.21 565.09 0.00 1.08 1.00
    4.00 1.00 149.21 2805.05 29.84 0.98 0.91
    4.00 2.00 151.98 2826.77 60.79 1.33 1.23
    4.00 3.00 155.36 2858.59 93.21 1.40 1.30
    4.00 4.00 173.78 3162.71 139.02 2.00 1.85
    4.00 5.00 144.52 2601.40 144.52 2.10 1.94
  • TABLE 17
    Library: Plate2 (ID: 100487) Unit: mg
    Row Col bead-pi-4 toluene Shell-EP-9 Shell-EP-2 Shell-EP-14 ethyl acetate BC (mmol/gr) SI (—)
    1.00 1.00 164.43 3091.28 8.22 24.66 0.00 0.00 0.66 0.87
    1.00 2.00 145.70 2709.98 14.57 43.71 0.00 0.00 0.27 0.36
    1.00 3.00 147.57 2715.23 22.14 66.41 0.00 0.00 0.26 0.35
    1.00 4.00 149.25 2716.30 29.85 89.55 0.00 0.00 0.54 0.71
    1.00 5.00 150.19 2703.46 37.55 112.64 0.00 0.00 0.46 0.60
    2.00 1.00 143.43 2696.48 9.56 19.12 0.00 0.00 0.57 0.76
    2.00 2.00 134.19 2495.93 17.89 35.78 0.00 0.00 0.57 0.76
    2.00 3.00 137.07 2522.03 27.41 54.83 0.00 0.00 0.56 0.74
    2.00 4.00 134.36 2445.32 35.83 71.66 0.00 0.00 0.53 0.70
    2.00 5.00 133.22 2398.03 44.41 88.82 0.00 0.00 0.51 0.68
    3.00 1.00 136.77 2386.69 6.84 0.00 20.52 184.64 0.50 0.66
    3.00 2.00 151.94 2415.77 15.19 0.00 45.58 410.22 1.14 1.52
    3.00 3.00 150.82 2164.30 22.62 0.00 67.87 610.83 1.50 1.98
    3.00 4.00 155.74 1993.42 31.15 0.00 93.44 840.97 1.12 1.48
    3.00 5.00 157.73 1774.47 39.43 0.00 118.30 1064.68 0.94 1.24
    3.00 6.00 153.01 575.59 0.00 0.00 0.00 0.00 0.75 1.00
    4.00 1.00 155.30 2733.19 10.35 0.00 20.71 186.35 0.50 0.67
    4.00 2.00 150.36 2435.83 20.05 0.00 40.10 360.86 1.03 1.36
    4.00 3.00 153.95 2278.47 30.79 0.00 61.58 554.22 1.36 1.80
    4.00 4.00 151.60 2031.43 40.43 0.00 80.85 727.68 1.38 1.83
    4.00 5.00 151.56 1818.68 50.52 0.00 101.04 909.34 1.24 1.64
  • TABLE 18
    Library: Plate1 (ID: 100486) Unit: mg
    Row Col bead-pi-4 toluene Shell-EP-9 Shell-EP-11 Shell-EP-2 Shell-EP-14 ethyl acetate BC (mmol/gr) SI (—)
    1.00 1.00 138.29 2599.76 27.66 0.00 0.00 0.00 0.00 0.69 0.95
    1.00 2.00 150.40 2797.48 60.16 0.00 0.00 0.00 0.00 0.62 0.85
    1.00 3.00 152.42 2804.49 91.45 0.00 0.00 0.00 0.00 0.59 0.82
    1.00 4.00 157.56 2867.65 126.05 0.00 0.00 0.00 0.00 0.44 0.61
    1.00 5.00 140.22 2523.91 140.22 0.00 0.00 0.00 0.00 0.40 0.56
    2.00 1.00 153.01 2876.51 0.00 30.60 0.00 0.00 0.00 0.40 0.55
    2.00 2.00 154.37 2871.30 0.00 61.75 0.00 0.00 0.00 0.32 0.44
    2.00 3.00 162.50 2989.96 0.00 97.50 0.00 0.00 0.00 0.43 0.60
    2.00 4.00 150.26 2734.64 0.00 120.20 0.00 0.00 0.00 0.36 0.49
    2.00 5.00 139.04 2502.74 0.00 139.04 0.00 0.00 0.00 0.44 0.61
    3.00 1.00 157.29 2957.05 0.00 0.00 31.46 0.00 0.00 0.29 0.40
    3.00 2.00 153.91 2862.71 0.00 0.00 61.56 0.00 0.00 0.33 0.45
    3.00 3.00 150.84 2775.51 0.00 0.00 90.51 0.00 0.00 0.40 0.55
    3.00 4.00 162.02 2948.67 0.00 0.00 129.61 0.00 0.00 0.35 0.49
    3.00 5.00 154.41 2779.43 0.00 0.00 154.41 0.00 0.00 0.38 0.53
    3.00 6.00 161.45 607.35 0.00 0.00 0.00 0.00 0.00 0.72 1.00
    4.00 1.00 156.49 2660.36 0.00 0.00 0.00 31.30 281.69 0.60 0.83
    4.00 2.00 157.65 2364.71 0.00 0.00 0.00 63.06 567.53 1.38 1.91
    4.00 3.00 157.12 2042.59 0.00 0.00 0.00 94.27 848.46 1.46 2.02
    4.00 4.00 153.24 1685.61 0.00 0.00 0.00 122.59 1103.31 1.37 1.89
    4.00 5.00 155.00 1395.01 0.00 0.00 0.00 155.00 1395.01 1.20 1.66
  • Example 5 Binding Capacity Measurements in a Non Interfering Buffer
  • An aliquot of dried resin of weight P(gr), is mixed under gentle agitation with a fixed volume, V(ml), of a phosphate ion solution of concentration Cstart(mM) buffered at pH 6.5. After resin equilibration, the solution is decanted by centrifugation and the supernatant analyzed for residual phosphate concentration by ionic chromatography, Ceq(mM). The binding capacity is calculated as BC (mmol/gr)=V. (Cstart−Ceq)/P.
  • Binding Capacity in a Ex-Vivo Aspirates
  • In this example healthy patients are given a meal of the same composition as the one prepared for the digestion mimic and aliquots of chyme are then sampled using a tube placed in the lumen of the small intestine.
  • Normal subjects are intubated with a double lumen polyvinyl tube, with a mercury weighted bag attached to the end of the tube to facilitate movement of the tube into the small intestine. One aspiration aperture of the double lumen tube is located in the stomach and the other aperture is at the Ligament of Treitz (in the upper jejunum). Placement takes place with the use of fluoroscopy.
  • After correct tube is placed, 550 mL of a liquid standard test meal (supplemented with a marker, polyethylene glycol (PEG)-2 g/550 mL) is infused into the stomach through the gastric aperture at a rate of 22 mL per minute. It requires approximately 25 minutes for the entire meal to reach the stomach. This rate of ingestion simulates the duration of time required to eat normal meals.
  • Jejunal chyme is aspirated from the tube whose lumen is located at the Ligament of Treitz. This fluid is collected continuously during 30-minute intervals for a two and a half hour period. This results in 5 specimens that are mixed, measured for volume, and lyophilized.
  • The phosphate binding procedure is identical to the one described earlier with the non-interfering buffer experiment, except that the ex-vivo aspirate liquid is used (after reconstitution of the freeze-dried material in the proper amount of de-ionized water). The binding capacity in the ex-vivo aspirate (VA) is calculated in the same way. Core-shell compositions bind more phosphate than the corresponding core component.
  • Example 6 Method of Selection of Semi-Permeable Membrane with High Potassium Binding Selectivity Over Magnesium and Calcium
  • This protocol describes a method to optimize polymeric materials with regards to their ion permselectivity characteristics, which then can be used as the shell component for the making of potassium selective core-shell ion-exchange particles.
  • Polymer Synthesis and Membrane Preparation:
  • Polymeric membrane materials with different compositions were prepared by radical copolymerization of DBA (N,N′-dibutyl acrylamide) and DEAEMA (N,N′-diethylaminoethylmethacrylate) in a glove box using miniaturized reactors in a library format. AIBN was used as the initiator and ethanol as the solvent. Polymers were isolated by precipitation into water, freeze-dried, and characterized by GPC and H-NMR. The composition of the polymer (DBA mol %) ranges from 30% to 70% and molecular weight ranges from 200K to 300K as shown below:
  • TABLE 19
    Polymer ID 101224
    D1 D2 D3 D4 D5 D6
    Mn (×103) 327 326 322 285 240 217
    Mw (×103) 584 563 520 467 411 340
    PDI 1.78 1.73 1.61 1.64 1.71 1.56
    Composition 31.2 37.1 48.5 56.1 64.4 68.5
    (DBA, mol %)
  • Polymer membranes were prepared by casting a 2-wt % toluene solution of DBA-co-DEAEMA onto a regenerated cellulose dialysis membrane (RC membrane with MWCO of 14 K). After toluene was evaporated, a polymer membrane was formed on the top of dialysis membrane. A composite membrane of polymer membrane and RC membrane was thus prepared.
  • Permeability Study on Cations
  • The composite membrane was first clamped onto a glass tube with diameter of 13 mm, and then immersed into a 2 L of donor solution of cations. The tube was filled with 10 ml of acceptor solution (lactose solution with the same osmolality as the donor solution (240 mM)). The acceptor solution was sampled at a specified time interval and analyzed by ion chromatography. See FIG. 3.
  • Donor solution was prepared by mixing the aqueous solution of NaCl, KCl, CaCl2.2H2O, and MgSO4.7H2O. The solution was buffered to pH 6 by using 14 mM of MES (2-[N-morpholine]ethanesulfonic acid] solution. The concentrations of different cations determined by IC were as follows: [Na+], 40.46 mM; [K+], 31.44 mM; [Mg2+], 33.25 mM; [Ca2+], 22.324 mM.
  • Determination of the permeability coefficient (P) of different cations: As mentioned in the measurement set-up, the acceptor solution was sampled at a specific time interval and analyzed by IC. Assuming a Fick's first law of diffusion, P is readily obtained by linearization of the data, following a method of calculation reported in equation 1 in G. Van den Mooter, C. Samyn, and R. Kinget, International Journal of Pharmaceutics, 111, 127-136 (1994). The permeability coefficients of different cations were thus calculated from the slope from this linear relationship.
  • - ln ( C o - C a c o ) = PS Va t Equation 1
  • Where Co is the initial concentration of the solute in the donor compartment and Ca the concentration in the acceptor compartment at time t, Va is the volume of the acceptor compartment, and S the surface of the membrane.
  • Permselectivity: As described above, the permeability coefficient was calculated for each cation. By normalizing the permeability coefficient of Na+ as 1, the permselectivity for cations M1 and M2 can be calculated as follows: PM1 M1=P(M2)/P(M1)
  • Permeability Coefficients of Different Cations Through Different Membranes:
  • Table 14 shows the permeability coefficients of different cations at different membranes. When polymers are more hydrophilic (Polymer D3 and D4 with DBA % 48.5 and 56.1%, respectively), all cations, such as Na+, K+, Mg2+, and Ca2+, are more permeable and their permeability coefficients are comparable to those through a blank dialysis membrane (RC membrane) and reflect the self-diffusivity of the cations. However, with the increasing DBA content in polymer membrane (See Table 20 for D5 and D6), the permeability coefficients of different cations decreased as compared with blank membrane, which means that the hydrophobic nature of polymer membrane could make cations less permeable through the hydrophobic barrier.
  • TABLE 20
    Permeability coefficients of cations at different membranes
    DBA PMg2+ PCa2+
    Polymer ID (mol %) PNa+ (cm/sec) PK+ (cm/sec) (cm/sec) (cm/sec)
    D3 48.5 2.41 (±0.26)E−4 3.11 (±0.34)E−4 6.50 (±0.08)E−5  6.0 (±0.07)E−5
    D4 56.1 4.28 (±0.44)E−5 6.11 (±0.61)E−4 1.13 (±0.11)E−5 1.04 (±0.05)E−5
    D5 64.4 4.32 (±0.20)E−6 5.79 (±3.59)E−6 5.42 (±4.11)E−7 3.32 (±3.33)E−7
    D6 68.5 1.50 (±0.05)E−7
  • Another characteristic for the permeability of different cations is their permselectivity. By normalizing the value of PNa + as 1, the permselectivity for other cations can be calculated and the results are shown in Table 21. The permselectivity of PMg/PNa and PCa/PNa decreases with the increasing DBA content in polymer membranes, which implies that more hydrophobic polymer membranes may have better selectivity for different cations. For a better selectivity for different cations, two factors should be considered—the charge density and the membrane hydrophobicity.
  • TABLE 21
    DBA P (K+)/ P (Ca2+)/ P (Mg2+)/ P (K+)/
    Polymer ID (%) P (Na+) P (Na+) P (Na+) P (Mg2+)
    D3 48.5 1.29 0.27 0.25 5.16
    D4 56.1 1.43 0.26 0.24 5.96
    D5 64.4 1.34 0.13 0.08 16.75
  • Example 7 Synthesis of poly-2-fluoroacrylic Acid Beads
  • Beads are prepared by a direct suspension process where a mixture of 2-fluoroacrylic methyl ester/divinylbenzene/benzoyl peroxide in a weight ratio 90/9/1 are dispersed in water under high shear with polyvinylalcohol as a suspending agent. The suspension is stirred and heated at 80° C. for 10 hours. The residual monomer is eliminated by steam stripping. The beads are then filtered and treated with aqueous 3M NaOH to hydrolyze the polymer, then washed, treated with HCL, water-washed, and finally dried to form the desired polyα-fluoroacrylic acid particles. The average bead diameter is 250 microns as measured by Master Sizer (Malvern UK).
  • Example 8 Preparation of poly-2-fluoroacrylic Acid/Core- (DBA-DEAEMA)/Shell Particles
  • The core-shell particles are prepared by forming a coating of polymer D2 on the poly-2-fluoroacrylic acid beads prepared in example 5 using a Wurster coater. The shell polymer prepared in example 4 is first dissolved at 20 wt-% in toluene, and the thus obtained solution then dispersed in water in a 1:4 weight ratio with 2 wt-% based on the organic phase of CTAB (Hexadecyltrimethyl-Ammonium Bromide) as a surfactant, using a Ultra-Turrax high-shear homogenizer. The toluene is then driven off by evaporation under reduced pressure. The average diameter of the dispersion particles is 0.3 micrometer, as measured by Dynamic Light Scattering. The poly-2-fluoroacrylic acid beads are spray-coated with the shell polymer dispersion using a Wurster fluid bed coater 2″-4″/6″ Portable Unit. The fluidized bed unit is operated so that an average 5 microns thick coating is deposited on the core particles.
  • Example 9 Preparation of Polystyrene Sulfonate/Core-Polyethyleneimine Shell Particles with Na+ and K+ Selective-Binding Properties Procedure for Coating PEI on Dowex Beads
  • PEI (poly(ethyleneimine), Mw10,000) and Dowex beads (H-form, X4-200) were purchased from commercial sources. PEI aqueous solutions with different concentrations were prepared by dissolving PEI directly into nanopure water.
  • Weighed dried Dowex beads were mixed with PEI aqueous solution in library format glass tubes. After a specified reaction time, the tubes were sealed and centrifuged at 1000 rpm for 15 minutes, the supernatant solutions were then decanted off. To the beads in each tube was added nanopure water to a total volume of 10 ml and all tubes were sealed and tumbled for 30 minutes. The same tumbling-centrifuging was repeated 3 times. The beads were freeze-dried and weighted until a constant weight was obtained.
  • The reaction solution composition and gel weight increase are displayed in Table 22.
  • TABLE 22
    Conditions for coating PEI on Dowex beads
    Dowex
    Bead PEI PEI Reaction Weight
    Weight Conc. volume time increase
    (gm) (wt %) (ml) (hours) Coated bead ID (Δwt %)
    0.1274 2.5 10 1 DOWEX (2.5 wt-1 h) *
    0.2223 2.5 10 6 DOWEX (2.5 wt-6 h) 3.1
    0.1609 1.5 10 1 DOWEX (2.5 wt-1 h) *
    0.2407 1.5 10 6 DOWEX (2.5 wt-6 h) 0.9
    0.2016 0.5 10 1 DOWEX (2.5 wt-1 h) *
    0.2347 0.5 10 6 DOWEX (2.5 wt-6 h) *
    * No weight increase was observed.
  • Method for Binding Study
  • A mixture of NaCl, KCl, MgCl2, and CaCl2 was dissolved in a MES buffer (pH6.0) (MES, 2-[N-morpholine]ethanesulfonic acid]. The concentration for each cation was determined by IC. The concentrations for Na+, K+, Mg2+, and Ca2+ are 26.4 mM, 9.75 mM, 4.75 mM and 4.16 mM respectively.
  • Weighed dried PEI-coated bead was put into a tube which contains 5-ml of MES buffer solution of NaCl, KCl, MgCl2, and CaCl2. The tube was sealed and tumbled. After a certain period of time as indicated in FIG. 4, the tube was centrifuged. 100 microliter of solution was then taken out from the supernatant for IC analysis. The binding amount of PEI coated beads for different cations were calculated from the concentration change in the solution.
  • The calculation is as follows:

  • Ion bound in beads(mmol/g)=[V×(C0−C t)/{[weight of beads]×1000}
  • C0: initial concentration of metal ion (in mM)
    Ct: concentration of metal ion after bead binding at a certain time (t hrs) (in mM)
    V: solution volume (5 ml)
  • Weight of Beads (gm)
  • The binding data of different PEI coated beads for different cations are shown in FIG. 4. PEI coated Dowex beads show higher Na+ and K+ binding than the uncoated beads (bare beads). The coated beads show much more selective binding than bare beads. The thicker the PEI coating (e.g. Dowex (2.5 wt-6 h), coated from 2.5 wt % PEI solution for 6 hours), the more selective for the different cations. The binding kinetic study shows that the binding of cations equilibrates faster for the thinner coated beads and bare beads.
  • Example 10 Polystyrene Sulfonate Beads with Eudragit Shell
  • Shell material: Eudragit RL100 (Rohm), a copolymer of acrylic and methacrylic acid esters with 8.85-11.96% cationic ammonio methacrylate units, 10 wt % in ethanol and 10 wt % triacetin. Core: Lewatit (cross-linked polystyrene sulfonate in sodium form), size—300 μm.
  • Figure US20090148533A1-20090611-C00018
  • The shell was applied using a FluidAir Wurster coater.
  • Binding was measured under following conditions:
  • Donor solution: 50 mM KCl and 50 mM MgCl2
  • Bead concentration: 4 mg/ml
  • Duration: 6 hours
  • FIG. 5 shows the effect of the shell on Mg2+ and K+ binding. With increasing ratio of shell to core, Mg2+ binding decreased and K+ binding increased. 20 wt % shell coating gave a K+ binding capacity of 1.65 meq/gm, which is about 3 times higher than for uncoated Dowex.
  • Example 11 Polystyrene Sulfonate Beads with Benzylated Polyethylene Imine Shell Synthesis of Benzylated Polyethyleneimine (PEI)
  • To a 250 ml of round bottom flask were charged 15.6 g of PEI (363 mmol of —NH2) and 125 ml of ethanol, this mixture was magnetically stirred until PEI was completely dissolved, then 30 g of NaHCO3 (FW, 84; 256 mmol) and 40 ml of benzyl chloride (363 mmol) were subsequently added. The above mixture was reacted at 55° C. under nitrogen atmosphere overnight. Dichloromomethane was added to the slurry reaction mixture, followed by filtration to remove inorganic salt. The solvent in filtrate was removed by vacuum. Dichloromethane was used again to re-dissolve the reaction product; inorganic salt was further removed by filtration. The solvent in the filtrate was removed again under vacuum. Finally, the product was triturated in hexane, filtered and washed with hexane, and dried under vacuum. The benzylation degree was 84% as determined by 1H NMR. Similar materials with various degree of benzylation (respectively 20% and 40% for Ben(20) and Ben(40)) were prepared by adjusting the benzyl chloride to PEI ratio.
  • Benzylated polyethylene imine (Ben-PEI) was coated onto Dowex beads.
  • Figure US20090148533A1-20090611-C00019
  • The shell was coated using solvent coacervation. The shell Ben(84)-PEI was dissolved in methanol and water mixture (3:1) at pH of 3. Shell and core were mixed for 5 minutes and methanol was removed by rotovap (40 minutes), isolated, washed, and dried.
  • Binding was measured under following conditions:
  • Donor solutions: 50 mM KCl and 50 mM MgCl2
  • Bead concentration: 4 mg/ml
  • Duration: 6 and 24 hours
  • Results of the binding measurements are shown in FIG. 6. Ben(84)-PEI showed selective binding for potassium after 6 and 24 hours as revealed by lower Mg2+ binding compared to naked beads.
  • FIG. 7 depicts the stability of Ben(84)-PEI coated Dowex (K) beads under acid conditions representative of the acidic conditions in the stomach. The beads were exposed to pH 2HCl for 6 hours, isolated, and dried. Binding selectivity was tested for the post-treated beads. Binding conditions were as follows:
  • Donor solutions: 50 mM KCl and 50 mM MgCl2
  • Bead concentration: 4 mg/ml
  • Duration: 6 and 24 hours
  • The coating was stable and binding selectivity was maintained at 6 and 24 hours.
  • Example 12 FAA Beads with Benzylated Polyethylene Imine Shell
  • The shell was applied on the FAA core by the process of solvent coacervation. The shell, Ben(84)-PEI, was dissolved in methanol and water mixture (3:1) at pH of 4.5. The shell and core were mixed for 5 minutes and methanol was removed by rotovap (40 minutes), isolated, washed, and dried.
  • Binding was measured under following conditions:
  • Donor solutions: 50 mM KCl and 50 mM MgCl2
  • Bead concentration: 4 mg/ml
  • Duration: 6 hours
  • The potassium binding was calculated from actual magnesium uptake and overall binding capacity of polymer which was 5.74 meq/gm. The results are shown in FIG. 8. Increasing the ratio of shell/core caused a decrease in magnesium binding which indicates an increase in potassium binding.
  • Example 13 Coating by Controlled Precipitation Induced by pH Change
  • The shell comprised of Benzylated PEI, Ben (˜20%); and Ben (˜40%) on a Dowex(K) core. Binding was measured in 50 mM KCl and 50 mM MgCl2.
  • FIG. 9 shows the results of the binding experiments. Controlled precipitation method for 40% benzylated PEI shows better coating and this combination of coating method and materials gives higher binding selectivity.
  • Example 14 Membrane Screening of Shell Polymers
  • Shell polymers were screened by coating a flat membrane via solvent casting and using the coated membrane as the barrier in a diffusion cell, as depicted in FIG. 10. Donor solution was 50 mM 2-[N-morpholino]ethane sulfonic acid (MES) buffer at pH6.5 with 50 mM K+ and Mg2+. Permeability coefficient was calculated as described in Example 4 above. Cross-linked B-PEI was tested using this method. B-PEI (35 mol %) was cross-linked with 1,4-butanediol diacrylate. The cross-linker was reacted on the top of dried B-PEI for 4 hours. The screening was performed in 50 mM KCl and 50 mM MgCl2 in 50 mM MES buffer. Cross-linker (diacrylate) reacted with B-PEI (35 mol %) membrane. As shown in FIG. 11, addition of the cross-linker reduced permeability coefficient and also showed good selectivity.
  • Blends of Eudragit RL 100 and RS 100 were also evaluated using the method of FIG. 10. The results are shown in FIG. 12. Adding RS 100 into RL 100 can reduce the permeability and the permselectivity stays in the same range. Membranes with more than 50 wt % of RS100 lost selectivity ([K+] in the same scale, but [Mg2+] much higher than other composites).
  • Example 15 Effects of Bile Acids on K+ Binding
  • Dowex(Li) (˜100 μm) was first coated with PEI aqueous solution. The supernatant was removed and the coat was further crosslinked with 1,2-Bis-(2-iodoethoxy)-ethane (BIEE). Binding was measured in 50 mM KCl and 50 mM of MgCl2, MES buffer, pH 6.5. Bile acids extract used was 2 mg/ml (bile extract porcine with 60% bile acids and 40% unknowns, i.e., free fatty acids, phospholipids, etc.). Time: 6 and 24 hrs and Bead content: 4 mg/ml. Results are shown in FIG. 13. Enhanced performance of the shell was observed in the presence of bile acids, fatty acids, and lipids.
  • All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
  • It will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

Claims (22)

1. A method for removing potassium from an animal subject in need thereof comprising administering core-shell particles comprising a core component encapsulated in a shell component to the patient, said core component comprising a potassium binding polymer, said shell component comprising a crosslinked amine functional polymer alkylated with hydrophobic agent(s).
2. The method of claim 1 wherein said core-shell particles have a capacity for binding potassium ion in a gastrointestinal tract of said animal subject.
3. The method of claim 2 wherein said core-shell particles retain a significant amount of said bound potassium ion during a period of residence of the core-shell particles in the gastrointestinal tract of said animal subject.
4. The method of claim 1 wherein the core component comprises crosslinked carboxylate, phosphonate, sulfate, sulfonate, sulfamate polymers or combinations thereof.
5. The method of claim 1 wherein the alkylating agents have the formula Rx where R is a C1-C20 alkyl, C1-C20 hydroxy-alkyl, C6-C20 aralkyl, C1-C20 alkylammonium, or C1-C20 alkylamido group and X comprises one or more electrophilic groups.
6. The method of claim 1 wherein the alkylating agent is an alkyl or alkylaryl group carrying an amine-reactive electrophile.
7. The method of claim 1 wherein the alkylating agent is selected from the group consisting of benzyl halide and dodecyl halide.
8. The method of claim 1 wherein the alkylating agent includes at least two electrophilic groups X.
9. The method of claim 8 wherein the alkylating agent is selected from the group consisting of di-haloalkane, dihalopolyethylene glycol, and epichlorohydrin.
10. The method of claim 1 wherein the shell thickness is from about 0.002 μm to about 50 μm.
11. The method of claim 1 wherein the shell to core weight ratio is 0.01% to 50%.
12. The method of claim 1 wherein the size of the core-shell particle is from about 200 nm to about 2 mm.
13. The method of claim 1 wherein the patient suffers from hyperkalemia, depressed renal synthesis of calcitriol, renal insufficiency, hypertension, chronic heart failure, end stage renal disease, fluid overload, and anabolic metabolism.
14. The method of claim 1 wherein the patient suffers from hyperkalemia.
15. A method of removing potassium from a patient in need thereof comprising administering core-shell particles to the patient, said core-shell particles comprising a core component encapsulated in a shell component, said core component comprising a crosslinked potassium binding polymer, said shell component comprising a crosslinked amine functional polymer alkylated with an alkyl or alkylaryl group.
16. The method of claim 15, the core component comprising crosslinked carboxylate, phosphonate, sulfate, sulfonate, sulfamate polymers or combinations thereof.
17. The method of claim 15 wherein the shell thickness is from about 0.002 gm to about 50 μm.
18. The method of claim 15 wherein the alkylating agent is a benzyl halide.
19. The method of claim 15 wherein the size of the core-shell particle is from about 200 nm to about 2 mm.
20. The method of claim 19 wherein the alkylating agent is a benzyl halide.
21. The method of claim 15 wherein the patient suffers from hyperkalemia, depressed renal synthesis of calcitriol, renal insufficiency, hypertension, chronic heart failure, end stage renal disease, fluid overload, and anabolic metabolism.
22. The method of claim 15 wherein the patient suffers from hyperkalemia.
US12/238,844 2004-03-30 2008-09-26 Ion binding compositions Active 2026-06-11 US8445014B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
US11/095,918 US7429394B2 (en) 2004-03-30 2005-03-30 Ion binding compositions
US12/238,844 US8445014B2 (en) 2004-03-30 2008-09-26 Ion binding compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/238,844 US8445014B2 (en) 2004-03-30 2008-09-26 Ion binding compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/095,918 Continuation US7429394B2 (en) 2004-03-30 2005-03-30 Ion binding compositions

Publications (2)

Publication Number Publication Date
US20090148533A1 true US20090148533A1 (en) 2009-06-11
US8445014B2 US8445014B2 (en) 2013-05-21

Family

ID=35054544

Family Applications (13)

Application Number Title Priority Date Filing Date
US11/095,760 Active 2025-05-01 US7776319B2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
US12/055,726 Active 2027-03-14 US8216560B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof
US12/055,746 Active 2027-05-29 US8282913B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof
US12/055,765 Active 2027-05-28 US8287847B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof
US12/238,844 Active 2026-06-11 US8445014B2 (en) 2004-03-30 2008-09-26 Ion binding compositions
US12/857,264 Active 2024-07-23 US8409561B2 (en) 2004-03-30 2010-08-16 Methods and compositions for treatment of ion imbalances
US13/015,134 Active US8475780B2 (en) 2004-03-30 2011-01-27 Ion binding polymers and uses thereof
US13/646,104 Abandoned US20130272990A1 (en) 2004-03-30 2012-10-05 Ion binding polymers and uses thereof
US13/647,690 Active 2024-04-29 US8778324B2 (en) 2004-03-30 2012-10-09 Ion binding polymers and uses thereof
US13/647,894 Active US8889115B2 (en) 2004-03-30 2012-10-09 Ion binding polymers and uses thereof
US14/295,950 Abandoned US20140286891A1 (en) 2004-03-30 2014-06-04 Ion binding polymers and uses thereof
US14/959,574 Abandoned US20160082039A1 (en) 2004-03-30 2015-12-04 Ion binding polymers and uses thereof
US15/210,226 Pending US20160317572A1 (en) 2004-03-30 2016-07-14 Ion binding polymers and uses thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US11/095,760 Active 2025-05-01 US7776319B2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
US12/055,726 Active 2027-03-14 US8216560B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof
US12/055,746 Active 2027-05-29 US8282913B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof
US12/055,765 Active 2027-05-28 US8287847B2 (en) 2004-03-30 2008-03-26 Ion binding polymers and uses thereof

Family Applications After (8)

Application Number Title Priority Date Filing Date
US12/857,264 Active 2024-07-23 US8409561B2 (en) 2004-03-30 2010-08-16 Methods and compositions for treatment of ion imbalances
US13/015,134 Active US8475780B2 (en) 2004-03-30 2011-01-27 Ion binding polymers and uses thereof
US13/646,104 Abandoned US20130272990A1 (en) 2004-03-30 2012-10-05 Ion binding polymers and uses thereof
US13/647,690 Active 2024-04-29 US8778324B2 (en) 2004-03-30 2012-10-09 Ion binding polymers and uses thereof
US13/647,894 Active US8889115B2 (en) 2004-03-30 2012-10-09 Ion binding polymers and uses thereof
US14/295,950 Abandoned US20140286891A1 (en) 2004-03-30 2014-06-04 Ion binding polymers and uses thereof
US14/959,574 Abandoned US20160082039A1 (en) 2004-03-30 2015-12-04 Ion binding polymers and uses thereof
US15/210,226 Pending US20160317572A1 (en) 2004-03-30 2016-07-14 Ion binding polymers and uses thereof

Country Status (11)

Country Link
US (13) US7776319B2 (en)
EP (3) EP1732523B9 (en)
JP (3) JP4974882B2 (en)
KR (3) KR101228233B1 (en)
AU (3) AU2005231424B2 (en)
BR (3) BRPI0509366B1 (en)
CA (3) CA2558029C (en)
DE (1) DE112005000730B4 (en)
GB (3) GB2430624B (en)
MX (1) MXPA06011270A (en)
WO (3) WO2005097081A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20100111891A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20110206631A1 (en) * 2004-03-30 2011-08-25 Relypsa, Inc. Ion binding polymers and uses thereof
US20110236340A1 (en) * 2008-08-22 2011-09-29 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029382T2 (en) 2003-08-26 2017-02-28 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
AT453383T (en) * 2004-03-30 2010-01-15 Relypsa Inc Ion-binding compositions
AU2006294455B2 (en) * 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
US8617609B2 (en) * 2005-09-30 2013-12-31 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
CN100398112C (en) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 Medicine for treating hyperphosphatemia and its preparing method
RU2443412C2 (en) * 2006-10-06 2012-02-27 Скил Текнолоджи Гмбх Dried reconstituted vesicles for pharmaceutical application
US20100324280A1 (en) * 2006-12-26 2010-12-23 Otsuka Pharmaceutical Factory, Inc. Sodium absorption inhibitor, potassium absorption inhibitor, phosphorus absorption inhibitor and preventive agent, therapeutic agent and food containing the same
US8779119B2 (en) 2006-12-26 2014-07-15 Jnc Corporation Metal salt of crosslinked cellulose derivative
CA2686414A1 (en) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
WO2009029841A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
JP5294681B2 (en) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 A substrate processing apparatus and a substrate transfer method
AU2013204877B2 (en) * 2008-08-22 2015-10-29 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
PT2550305T (en) 2010-03-20 2018-04-20 Relypsa Inc Continuous process for preparing polyfluoroacrylate particles
CN103534209A (en) 2011-02-11 2014-01-22 Zs制药公司 Microporous zirconium silicate for the treatment of hyperkalemia
CN105001120B (en) 2011-06-27 2018-04-13 瑞立普萨公司 Fluorinated acrylates and derivatives
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
EP2872148A4 (en) 2012-07-11 2016-06-15 Zs Pharma Inc Zirconium silicate for treatment of hyperkalemia
CA2879425A1 (en) * 2012-07-19 2014-01-23 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers
KR101694080B1 (en) 2012-08-09 2017-01-06 데페익스 피네 케미칼스 오스트리아 게엠베하 운트 코 카게 Process for drying polymeric materials
WO2014058905A2 (en) 2012-10-08 2014-04-17 Relypsa, Inc. Potassium-binding agents for treating hypertension and hyperkalemia
WO2014066407A1 (en) 2012-10-22 2014-05-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia
AU2014274817B2 (en) 2013-06-05 2019-05-23 Tricida, Inc. Proton-binding polymers for oral administration
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (en) * 2014-09-30 2019-02-13 積水化成品工業株式会社 Hollow resin particles and a method of manufacturing the same
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (en) 2015-12-23 2017-06-23 Rjw Pharma Llc Process for the synthesis of patiromer

Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3874907A (en) * 1972-02-16 1975-04-01 Rhone Poulenc Sa Microcapsules for use in artificial kidney machines
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4605701A (en) * 1983-10-25 1986-08-12 Nitto Boseki Co., Ltd. Small-globular crosslinked monoallylamine polymer and process for producing the same
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US4902501A (en) * 1986-06-16 1990-02-20 Prodotti Formenti S.R.L. Pharmaceutical compositions endowed with sequestering activity for the biliary acids, containing colestyramin as their active principle, and process for preparing them
US4942205A (en) * 1987-02-17 1990-07-17 Daikin Industries, Ltd. Alpha-fluoroacrylic acid polymer and its use
US5051253A (en) * 1988-07-16 1991-09-24 Reckitt & Colman Products Limited Use of polyacrylates to reduce proteolytic activity in the human intestinal tract
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
US5141927A (en) * 1990-07-04 1992-08-25 Marcin Krotkiewski Antihypertensive preparation comprising an alginate and vitamin D
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
US5374422A (en) * 1989-07-19 1994-12-20 Lowchol Scientific, Inc. Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol
US5401498A (en) * 1992-03-28 1995-03-28 Hoechst Aktiengesellschaft Pharmaceuticals comprising polyhydroxymethylene derivatives, process for their preparation and use
US5413782A (en) * 1990-12-19 1995-05-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding pharmaceuticals to ion exchange resins
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5633344A (en) * 1992-08-20 1997-05-27 E. I. Du Pont De Nemours & Company Crosslinked polymeric ammonium salts
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5679717A (en) * 1994-06-10 1997-10-21 Geltex Pharmaceuticals, Inc. Method for removing bile salts from a patient with alkylated amine polymers
US5718920A (en) * 1993-11-25 1998-02-17 Salternate B.V. Particles for binding monovalent cations
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US20020054913A1 (en) * 1996-06-28 2002-05-09 Gerd-Ulfert Heese Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US20020146386A1 (en) * 2000-11-20 2002-10-10 Jaime Simon In vivo use of water absorbent polymers
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US20030065090A1 (en) * 2001-05-16 2003-04-03 Kelly Michael Dewayne Polyaniline coating composition
US20040166156A1 (en) * 1999-10-19 2004-08-26 Genzyme Corporation Direct compression polymer tablet core
US20040251204A1 (en) * 2003-02-25 2004-12-16 Finnfeeds Finland Oy Separation system and process
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20050220889A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220890A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220752A1 (en) * 2004-03-30 2005-10-06 Dominique Charmot Ion binding polymers and uses thereof
US20050220751A1 (en) * 2004-03-30 2005-10-06 Dominique Charmot Ion binding polymers and uses thereof
US20060024336A1 (en) * 2004-03-30 2006-02-02 Dominique Charmot Ion binding compositions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) * 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
SE8003805L (en) 1980-05-21 1981-11-22 Haessle Ab A pharmaceutical formulation forbettrade utlosningsegenskap
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (en) 1980-08-22 1982-04-01 Bayer Ag A process for the preparation of bead polymers of uniform particle size
DE3149136C2 (en) * 1981-12-11 1990-05-31 Robert Bosch Gmbh, 7000 Stuttgart, De
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
KR920006865B1 (en) 1984-05-18 1992-08-21 파트릭 에프. 라이스 Method and apparatus for coating particles or liquid droplets
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (en) * 1988-06-30 1991-09-27 Cortial New pharmaceutical form is sustained release-based resin of a complex active-principle
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
DE3928990A1 (en) 1989-09-01 1991-03-07 Bayer Ag A process for the preparation of (alpha) -fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (en) 1996-06-11 2007-02-21 株式会社大塚製薬工場 Guanidino compounds lowering agents as well as water and potassium ion adsorbent
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
CA2258744A1 (en) * 1996-06-27 1997-12-31 Washington University Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
JPH10130154A (en) 1996-10-29 1998-05-19 Kao Corp Life prolongation ratio improver for nephritis patient
BR9813808A (en) 1997-12-19 2002-05-28 Smithkline Beecham Corp Process for the production of tablets to be dispersed in Bite
AU1714000A (en) * 1998-11-06 2000-05-29 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
JP2002534374A (en) * 1999-01-07 2002-10-15 エラン コーポレーシヨン ピーエルシー Multiparticulate oral dosage forms
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
FR2812632B1 (en) 2000-08-07 2003-03-07 Solvay Process for the synthesis of compounds fluoroorganiques
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
JP2004149525A (en) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd Potassium ion adsorbent, method for producing the same, and therapeutic agent for hyperkalemia
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
EP1732523B9 (en) 2004-03-30 2010-06-02 Relypsa, Inc. Potassium binding polymers and uses thereof
US8617609B2 (en) 2005-09-30 2013-12-31 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2010022382A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions

Patent Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3874907A (en) * 1972-02-16 1975-04-01 Rhone Poulenc Sa Microcapsules for use in artificial kidney machines
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4605701A (en) * 1983-10-25 1986-08-12 Nitto Boseki Co., Ltd. Small-globular crosslinked monoallylamine polymer and process for producing the same
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
US4902501A (en) * 1986-06-16 1990-02-20 Prodotti Formenti S.R.L. Pharmaceutical compositions endowed with sequestering activity for the biliary acids, containing colestyramin as their active principle, and process for preparing them
US4942205A (en) * 1987-02-17 1990-07-17 Daikin Industries, Ltd. Alpha-fluoroacrylic acid polymer and its use
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5051253A (en) * 1988-07-16 1991-09-24 Reckitt & Colman Products Limited Use of polyacrylates to reduce proteolytic activity in the human intestinal tract
US5374422A (en) * 1989-07-19 1994-12-20 Lowchol Scientific, Inc. Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
US5141927A (en) * 1990-07-04 1992-08-25 Marcin Krotkiewski Antihypertensive preparation comprising an alginate and vitamin D
US5413782A (en) * 1990-12-19 1995-05-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding pharmaceuticals to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
US5401498A (en) * 1992-03-28 1995-03-28 Hoechst Aktiengesellschaft Pharmaceuticals comprising polyhydroxymethylene derivatives, process for their preparation and use
US5633344A (en) * 1992-08-20 1997-05-27 E. I. Du Pont De Nemours & Company Crosslinked polymeric ammonium salts
US5702696A (en) * 1993-05-20 1997-12-30 Geltex Pharmaceuticals Iron-binding polymers for oral administration
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5718920A (en) * 1993-11-25 1998-02-17 Salternate B.V. Particles for binding monovalent cations
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5679717A (en) * 1994-06-10 1997-10-21 Geltex Pharmaceuticals, Inc. Method for removing bile salts from a patient with alkylated amine polymers
US5693675A (en) * 1994-06-10 1997-12-02 Geltex Pharmaceuticals Inc. Alkylated amine polymers
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US20020054913A1 (en) * 1996-06-28 2002-05-09 Gerd-Ulfert Heese Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US20040166156A1 (en) * 1999-10-19 2004-08-26 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US20020146386A1 (en) * 2000-11-20 2002-10-10 Jaime Simon In vivo use of water absorbent polymers
US20050036983A1 (en) * 2000-11-20 2005-02-17 Jaime Simon In vivo use of water absorbent polymers
US20030065090A1 (en) * 2001-05-16 2003-04-03 Kelly Michael Dewayne Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20040251204A1 (en) * 2003-02-25 2004-12-16 Finnfeeds Finland Oy Separation system and process
US20060024336A1 (en) * 2004-03-30 2006-02-02 Dominique Charmot Ion binding compositions
US20050220889A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220890A1 (en) * 2004-03-30 2005-10-06 Symyx Therapeutics, Inc. Ion binding compositions
US20050220752A1 (en) * 2004-03-30 2005-10-06 Dominique Charmot Ion binding polymers and uses thereof
US20050220751A1 (en) * 2004-03-30 2005-10-06 Dominique Charmot Ion binding polymers and uses thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475780B2 (en) 2004-03-30 2013-07-02 Relypsa, Inc. Ion binding polymers and uses thereof
US20110206631A1 (en) * 2004-03-30 2011-08-25 Relypsa, Inc. Ion binding polymers and uses thereof
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20100111891A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20110236340A1 (en) * 2008-08-22 2011-09-29 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
US9908951B2 (en) 2011-06-27 2018-03-06 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid

Also Published As

Publication number Publication date
CA2557848C (en) 2013-12-10
CA2557848A1 (en) 2005-10-20
KR101199608B1 (en) 2012-11-08
US20060024265A1 (en) 2006-02-02
US8409561B2 (en) 2013-04-02
EP1732516B1 (en) 2009-12-30
GB2430368A (en) 2007-03-28
MXPA06011270A (en) 2007-03-08
CA2557999C (en) 2013-11-12
JP4964122B2 (en) 2012-06-27
AU2005231383B2 (en) 2010-06-10
JP4974882B2 (en) 2012-07-11
US20110033505A1 (en) 2011-02-10
US20110206631A1 (en) 2011-08-25
US20160082039A1 (en) 2016-03-24
KR20060135044A (en) 2006-12-28
GB2430624B (en) 2009-08-05
GB0621241D0 (en) 2006-12-13
DE112005000730T5 (en) 2008-07-03
KR101228233B1 (en) 2013-01-31
US8216560B2 (en) 2012-07-10
JP2007531758A (en) 2007-11-08
JP5000480B2 (en) 2012-08-15
EP1732524A2 (en) 2006-12-20
US8778324B2 (en) 2014-07-15
US20130272990A1 (en) 2013-10-17
US20080241093A1 (en) 2008-10-02
GB2430367A (en) 2007-03-28
EP1732523B9 (en) 2010-06-02
EP1732524A4 (en) 2007-09-19
US8287847B2 (en) 2012-10-16
WO2005094384A3 (en) 2006-01-26
US20080233073A1 (en) 2008-09-25
US20130272991A1 (en) 2013-10-17
US20140286891A1 (en) 2014-09-25
BRPI0509365A (en) 2007-09-04
EP1732523A4 (en) 2007-06-06
US8445014B2 (en) 2013-05-21
AU2005231424A1 (en) 2005-10-20
EP1732523B1 (en) 2010-03-17
US8282913B2 (en) 2012-10-09
AU2005231424B2 (en) 2010-06-17
BRPI0509331B1 (en) 2018-11-27
US20080241092A1 (en) 2008-10-02
EP1732524B1 (en) 2012-08-22
GB2430367B (en) 2009-08-05
AU2005231383A1 (en) 2005-10-20
EP1732516A1 (en) 2006-12-20
BRPI0509366A (en) 2007-09-04
EP1732523A1 (en) 2006-12-20
CA2557999A1 (en) 2005-10-13
KR20060135045A (en) 2006-12-28
CA2558029A1 (en) 2005-10-20
GB0621244D0 (en) 2006-12-13
BRPI0509366B1 (en) 2018-07-24
EP1732516A4 (en) 2007-06-06
JP2007531774A (en) 2007-11-08
US8889115B2 (en) 2014-11-18
GB2430368B (en) 2009-08-26
US7776319B2 (en) 2010-08-17
BRPI0509365B1 (en) 2018-06-12
US20160317572A1 (en) 2016-11-03
US20130272992A1 (en) 2013-10-17
KR101153035B1 (en) 2012-06-11
CA2558029C (en) 2013-05-07
GB2430624A (en) 2007-04-04
JP2007531726A (en) 2007-11-08
BRPI0509331A (en) 2007-09-04
WO2005094384A2 (en) 2005-10-13
US8475780B2 (en) 2013-07-02
DE112005000730B4 (en) 2017-12-21
WO2005097072A1 (en) 2005-10-20
WO2005097081A1 (en) 2005-10-20
KR20070007168A (en) 2007-01-12
AU2005228696B2 (en) 2010-06-24
GB0621242D0 (en) 2006-12-13
AU2005228696A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
JP4480801B2 (en) Formulations and methods of generating it improves the bioavailability of the absorption challenging agent
US6083497A (en) Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
JP3113283B2 (en) Phosphate binding polymers for oral administration
RU2160742C2 (en) Method of withdrawing gall-stones from patent's body (variants) and alkylated cross-linked polymer for carrying in through
Raghunathan et al. Sustained‐release drug delivery system I: Coated ion‐exchange resin system for phenylpropanolamine and other drugs
US7459305B2 (en) Ingestible gastrointestinal device
ES2307044T3 (en) Multilayer pharmaceutical form containing a substance with modulatory activity in what respects to the release of the active ingredient.
Bagre et al. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment
ES2200306T3 (en) Micro-particles of gelatin to chitosan.
EP1044008B1 (en) Use of aliphatic polyamines for reducing oxalate
US6290947B1 (en) Ionic polymers as toxin-binding agents
FI85216C (en) Foerfarande Foer farmstaellning of a oralt administrerbart of pharmaceutical preparat of 5-amino-salicylsyra.
EP1014999B1 (en) Cationic polymers as toxin-binding agents
EP2187876B1 (en) Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
ES2248292T3 (en) Multilayer pharmaceutical formulation for colon release.
AU2004311849B2 (en) Enteric coated aliphatic amine polymer bile acid sequestrants
DK200300005U3 (en) Pharmaceutical pellets containing tamsulosin
US20030039627A1 (en) Method for treating gout and binding uric acid
ES2716982T3 (en) Aliphatic amine polymer salts for the manufacture of tablets
KR100646114B1 (en) Coating and excipient agent for oral or dermal dosage forms
KR101200286B1 (en) Pharmaceutical formulation for the active ingredient budesonide
US7335795B2 (en) Crosslinked amine polymers
JP4499363B2 (en) Method of reducing serum glucose
EP0996454B1 (en) Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia
CA2542730C (en) Anion-binding polymers and uses thereof

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: CANTOR FITZGERALD SECURITIES, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNOR:RELYPSA, INC.;REEL/FRAME:038394/0034

Effective date: 20160427

AS Assignment

Owner name: ILYPSA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHARMOT, DOMINIQUE;CHANG, HAN-TING;CONNOR, ERIC;AND OTHERS;SIGNING DATES FROM 20050425 TO 20050428;REEL/FRAME:038545/0434

Owner name: RELYPSA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ILYPSA, INC.;REEL/FRAME:038545/0642

Effective date: 20080108

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: RELYPSA, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CANTOR FITZGERALD SECURITIES;REEL/FRAME:039621/0142

Effective date: 20160901